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INTRODUCTION 
 
Pseudomonas aeruginosa has become one of the most dreadful 
causes of nosocomial bacterial infections especially in the lung, blood 
and urinary tract. As a result of its considerable potential to become 
resistant to many antibiotics, more multidrug resistant strains are 
encountered as clinical isolates, leaving physicians with a decreasing 
armamentarium of effective drugs for treatment. 
Before the advent of modern medical microbiology, there was 
evidence that P.aeruginosa was a cause of serious wound and surgical 
infections, as elaborated by Doggett .In 1850, it was noted by Sedillot 
that there were sometimes blue green discharges on surgical dressings 
that were associated with infection. In 1862, Luke noted rod-shaped 
microscopic entities within the blue green pus. In 1882, Gessard 
isolated the organisms and originally designated them as bacillus 
pyocyaneus, and other early Microbiologists also isolated the 
organism from infected sites. Osler in 1925, thought that the 
organism to be more of a secondary opportunistic invader of damaged 
tissues as opposed to a primary cause of infection in healthy tissues. 
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P. aeruginosa has emerged as a major human pathogen in the 
1960’s, since it can cause infection in immunosuppressed and burns 
patients as well as cystic fibrosis patients, all of whom were surviving 
much longer with advanced medical treatments. 
Community acquired P.aeruginosa infection is most 
commonly associated with exposure to moist environments. 
P.aeruginosa skin infections which are related to use of whirl pools, 
hot tubs swimming pools and other types of baths are well recognized 
clinical presentation of community-acquired infection. 
P.aeruginosa nosocomial infections are usually acquired in the 
hospital, particularly in patients on mechanical ventilation, antibiotic 
therapy, chemotherapy (or) postsurgery.  Endogenous P.aeruginosa 
brought into ICUs by patients from the community can serve as 
sources of serious infection. With increasing problems due to 
infection with P.aeruginosa strains which are resistant to multiple 
antibiotics due to inherent and acquired resistance, therapeutic 
problems with this organisim will remain an imporant cause of 
morbidity and mortality in tertiary care centres. Biofilm formation on 
implanted medical devices from venous catheters to orthopedic 
implants favours the organism to colonize and disseminate 
systemically. 
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DISCOVERY OF ANTIBIOTICS & ANTIMICROBIAL 
RESISTANCE 
EVOLUTION OF ANTIMICROBIAL RESISTANCE IN 
PSEUDOMONAS 
Discovery of antimicrobials is one of the most important 
developments in modern medicine. The modern era of chemotherapy 
began in 1935 after the discovery of Sulphonamides by German 
chemist Gerhard Domagk [40] which was marketed by Bayer by the 
trade name Prontosil. 
Penicillin was discovered by Alexander fleming in 1928 [83] 
and it was therapeutically used by Howard Florey in 1940. 
Streptomycin was discovered by an American microbiologist Selman 
Walksman[22] in 1943. In 1948, Cephalosporin was identified by 
Brotzu[41] and  introduced for therapeutic use in 1964.Within a very 
short period after its discovery 1943,resistance to penicillin was 
developed by many microorganisms. In the recent years, resistance to 
Cephalosporins and Carbapenems of the Betalactam group have 
emerged in bacteria leaving behind a very few antibiotics in the tunnel 
for treatment of the multidrug resistant organisms which pose serious 
therapeutic concern. 
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ANTIBIOTIC RESISTANCE: 
 The mechanisms of bacterial resistance are complex and varied 
[59]
.
Antimicrobial resistance could be biological Vs clinical, 
environmentally mediated or microorganism mediated. During the 
past twenty five years, alarming number of bacterial strains have 
evolved with resistance to antimicrobial agents[75] .This resistant 
microbial strains have become one of the major concerns of the 
clinicians, microbiologists and public health officials.   Although genes 
for mediation of bacterial resistance might have existed before the 
clinical use of antibiotics, selection of newer resistant strains is mainly 
by the widespread use of antimicrobials. The most commonly used 
antibiotics in clinical medicine are the beta-lactam antibiotics and the 
most common mechanism of resistance to these agents is inactivation 
by Beta-lactamases. The clinical consequences of therapeutic failure 
and relapse has extended hospital stays, increased morbidity and 
mortality, and necessitated the use of potentially more toxic and costly 
drugs which  require newer strategies to prevent the spread of resistant 
strains and thereby limit future resistance.                                                   
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EMERGENCE OF NEWER BETALACTAMASES 
 Pseudomonas aeruginosa is known to be one of the most 
common pathogens causing hospital acquired infections [50]. 
Carbapenems are the drugs of choice for the treatment of infections 
caused by multidrug resistant Gram negative bacilli. Heavy pressure 
of antibiotic usage has lead to the emergence of newer β- lactamases 
with a wide spectrum of activity.  
  Among the various β - lactamases, the Carbapenemases, 
importantly transferrable Metallobetalactamases are the most worried 
due to their ability to hydrolyze almost all drugs in that class 
including the Carbapenems. Metallobetalactamases can hydrolyze all 
Beta lactams except Monobactams and are not inhibited by β-
lactamase inhibitors like Clavulanic acid, Tazabactam or Sulbactum. 
Metallobetalactamase producing strains are usually resistant to 
Aminoglycosides and Fluoroquinolnes [132]. However they are 
sensitive to Polymyxins[133].  
The first Metallobetalactamase was reported from Bacillus 
cereus in the 1960s and since then 18 different Metallobetalactamases 
have been detected in various Gram-negative bacteria. Production of 
most of these Metallobetalactamases is chromosomally mediated and 
did not pose any serious threat of dissemination to other bacteria. The 
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first metallo β lactamase producing P.aeruginosa strain which was 
plasmid mediated was isolated in Japan in 1988[133]. For many years, 
these MBL producing isolates were restricted to Japan, but now it has 
disseminated worldwide [24].In India, Metallobetalactamase producing 
P.aeruginosa  was first documented in the year 2002 [90]
. 
           With the world wide  increase in the occurrence and  spread  of 
Metallobetalactamases, early detection of these strains is crucial, as 
this would benefit by  timely implementation of preventive measures 
like strict infection control practices and therapy with alternative 
antibiotics [92].As such organisms are being difficult to detect , they are  
posing significant risks, particularly due to unnoticed spread within 
institutions and their potential to participate in horizontal MBL gene 
transfer with other organisms in the hospital[92].  
          The genes encoding for MBL are typically part of an integron 
and they are either carried on transferable plasmids or as part of the 
bacterial chromosome [131].  . Recently, the most common transferable 
MetalloBetaLactamase families include the VIM, IMP, GIM, SPM, 
and SIM type enzymes which have been detected worldwide primarily 
in Pseudomonas aeruginosa but were also detected in other Gram-
negative bacteria, including the non-fermentors like Acinetobacter 
spp. and members of the family Enterobacteriaceae[112].     
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          Two new subgroups of Metallobetalactamases, designated as 
NDM-1 and DIM-1, were identified recently, in a clinical isolate of 
Klebsiella pneumoniae in India and in Pseudomonas stutzeri in 
Netherlands, respectively. Such enzymes are emerging in many 
geographical locations and often mediate very high level resistance to 
all β lactams except Aztreonam. 
      Recently, there is an emergence of Carbapenem susceptible 
isolates often carrying MBL genes which are hidden, whereby the 
Microbiologists, clinicians and medical fraternities remain unaware of 
their presence within the institution [20]. These organisms can appear 
sensitive to Carbapenems though they carry the carbapenemases. To 
overcome this, new phenotypic method using both Combined disc test 
and Double disc synergy test on the same agar plate has been 
developed, that is supposed to be highly sensitive and specific at 
detecting both Carbapenem sensitive and Carbapenem resistant 
isolates across worldwide. 
           Since there are no CLSI guidelines for detection of 
Metallobetalactamases, different studies have used different methods. 
Despite PCR being highly accurate and reliable, its accessibility is 
limited only to reference laboratories [32]. Various non-molecular 
methods have been studied, all by using the enzyme’s zinc 
14 
 
dependence activity. Chelating agents, such as 2-mercaptopropionic 
acid, EDTA and other thiol compounds are used to inhibit its     
activity [32]
. 
       The various phenotypic methods used to detect MBL are the 
Combined disc diffusion test, Double disc synergy test, Modified 
hodge test and E-test. Other less commonly performed tests are Re-
modified hodge test, EDTA-Imipenem Microbiological assay, broth 
microdilution test. The combined disc diffusion test is based on the 
principle that in the presence of EDTA, MBL enzyme gets inhibited 
thus increasing the zone diameter of Imipenem when EDTA is added 
to it than when tested alone. In the Double disc synergy test, 
Imipenem or Ceftazidime discs are placed 15-20 mm apart from plain 
filter paper disc and when EDTA solution is added to the plain disc 
and incubated, the formation of an extended zone of inhibition from 
Ceftazidime or Imipenem towards EDTA is interpreted as positive. 
The Modified hodge test is the test for carbapenemase production 
which is based on the principle that in the presence of an indicator 
strain E.coli ATCC 25922, the test strain if it produces 
carbapenemase, it will diffuse in the culture medium and the sensitive 
indicator strain will grow even in the presence of Imipenem in the 
vicinity of the test strain producing a clover leaf-like indendation. In 
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the E-Test, the presence of EDTA in the test strip reduces the MIC for 
Imipenem by ≥ 3 twofold dilutions if the test strain is an MBL 
producer. The genotypic method to detect and confirm MBL is the 
PCR which identifies the genes encoding for MBL production. 
           Hence, the present study is undertaken to study the prevalence 
of MBL in Pseudomonas in our locality and various methods are 
compared to evaluate a simple, cost effective and feasible method 
which shows sensitivity and specificity equivalent to PCR to detect 
MBL production & thereby reduce the transmission of resistance 
strains in the community.   
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AIMS AND OBJECTIVES 
 
 To study the prevalence of MBL production in Pseudomonas 
aeruginosa isolates from patients admitted to various clinical 
departments in Govt.Rajaji Hospital, Madurai. 
 To Identify and confirm MBL production in Pseudomonas 
aeruginosa isolates by phenotypic and genotypic methods. 
 To compare various phenotypic  methods in the detection of  MBL 
with genotypic method(PCR)  and to evaluate a simple, cost 
effective and sensitive method to detect MBL production at the 
earliest  that can be recommended for  routine screening of MBL in 
Microbiological laboratories  & thereby reduce the transmission of 
resistant strains in the community. 
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REVIEW OF LITERATURE 
Infectious diseases have been inextricably linked with human 
health, affecting the development and advancement of societies as well as 
human evolution [88]. Nosocomial infections are infections causing a 
serious threat to the community and are reported in 5-10 percent of 
hospital admissions throughout the world. In India, the nosocomial 
infection rate is alarmingly rising and is estimated to be about 30-35 
percent of all the hospital admissions [33]. 
With the advent of more elaborate surgical procedures and 
intensive care, combined with the use of broad spectrum antibiotics and 
immunosuppressive drugs, the highly virulent Gram negative bacteria 
have increased in importance in causing nosocomial infections [82] and 
show high resistance to treatment. 
P.aeruginosa is opportunist capable of causing infection in 
immunocompromised patients. In clinical medicine, P. aeruginosa has 
been primarily encountered as a nosocomial pathogen, which reflects its 
great propensity to grow in a variety of environment with minimal 
nutritional components [89].It is usually found in water, soil and plants and 
associated with colonisation of healthy human and animals. Up to 7% of 
healthy humans are colonised by P.aeruginosa in the nasal mucosa, throat 
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or on the skin and a high rate of 24% carriage rates in the stool are 
reported [76].The organism can tolerate temperatures as high as 45◦C to 
50◦C and can grow in distilled water using dissolved CO2 and residual 
iron, sulfur, phosphorus, and divalent cations such as carbon which 
enhance the growth of P.aeruginosa even in antiseptic solutions and other 
liquids. 
Within the health care setting, P.aeruginosa colonizes moist 
surfaces of patients’ ear, axilla and perineum and is also found in moist 
inanimate environments including water in sinks, toilets and showers 
including antiseptic solutions which are used in the wards [87]. Hospital 
equipments such as respiratory ventilators, cleansing solutions, mops are 
also sources of P.aeruginosa infection. 
The primary factor determining the pathogenic potential of 
P.aeruginosa is the immunological status of the human host. One 
important predisposing factor for community acquired and nosocomial 
P.aeruginosa infection is neutropenia [113]. Disruption in anatomic barrier 
functions of skin and mucosal surfaces causes invasive infection. 
Patients with significant burn wounds are at high risk for 
P.aeruginosa[120]. Burn wounds, other types of wounds such as chronic 
non-healing ulcer ,diabetic ulcer ,ulcers due to malignancies, use of 
intravenous or urinay catheters, use of endotracheal tubes are 
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predisposing factors to acquire infection with P.aeruginosa.  In burned 
skin, stieritz and holder [127] showed that P. aeruginosa grew to high 
levels after inoculation as few as 10 organisms, after which there was 
systemic dissemination and lethality. Though the healthy eye is highly 
resistant to P.aeruginosa infection, when the physical integrity of corneal 
epithelium is lost, it becomes a pathogen [28, 65, 21].The organism can also 
cause dreadful infections of the eye. Pseudomonas keratitis and 
endophthalmitis must be approached as medical emergency that can be 
fatal and threaten permanent loss of vision [28]
.
 Loss of mucosal barrier is 
also an important factor in invasive disease. Soluble host factors that have 
been implicated in high level resistance to P.aeruginosa infection include 
complement proteins [141,107] lung surfactants [91] and similar members of 
collectin family a variety of cytokines and chemokines[48]  . 
P.aeruginosa is highly pathogenic in humans because of the 
multitude, diversity and complexity of its virulence factors. The organism 
has a large genome more than 6 mega bases in size that is highly plastic 
in terms of ability to incorporate and modify DNA [124]
.
 All major classes 
of bacterial virulence systems are virtually found in  this organism 
including exotoxins, endotoxins, leukocidin, type III secreted toxins, 
fimbriae, flagella, neuraminidase, elastase, proteases,  exoenzymes, 
phospolipases, iron binding proteins, exo-polysaccharides 
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(alginate),bacteriocins, biofilm  formation [27] and pigment production  
such as pyocyanins[62]. 
Biofilms are formed on implanated medical devices from venous 
catheters to orthopaedic implants on which the organism can colonize and 
disseminate systemically. One of the major bacterial factors implicated in 
pathogenesis is elastase[118]
.
  Iron levels regulate the ability of 
P.aeruginosa to produce exotoxin, one of the bacterial exoproteins that 
plays an important role in pathogenesis [107,111]
.
 It uses siderophore 
systems to acquire iron [16].  The two well studied iron acquisition systems 
in P.aeruginosa are involving the pigments pyoverdin and pyochelin. 
Pyocyanin, the blue phenazine pigment partly responsible for the colour 
of P.aeruginosa on agar plates, is also detectable in the sputum of CF 
patients, indicating in vivo production. The production of mucoid 
morphotype is due to the production of large amounts of polysaccharide 
(alginate) [98], which is ultimately responsible for the poor prognosis and 
high mortality rates among patients with cystic fibrosis [80]
. 
Recently, small regulatory RNAs have been recognized whose 
expression is controlled by a repressor protein fur and these regulator 
RNAs control production of factors known as quorum sensors that 
signal the organism how to respond to its environment. 
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QUORUM SENSING - VIRULENCE FACTOR PRODUCTION & 
BIOFILM FORMATION: 
The enormous use of implantable devices in modern clinical 
medicine has led to the formation of structured  bacterial communication 
known as biofilms on these devices and contribute to infection[27]  .Using  
in vitro  systems , it has been shown that QS molecule are needed  for the 
production of structured P.aeruginosa bio films. These structures are also 
produced under conditions of flow of nutrient media over a solid surface 
where the bio film is forming unlikely to be present in lung or bone but 
present in vascular tissues [136]. When the bacterial counts increase in a 
tissue, the organisms reach a critical mass that is thought to allow them to 
communicate effectively with each other through a system of quorum 
sensing (QS) [25]
.
 At critical bacterial masses, low molecular weight 
mediators of the QS response are synthesized secreted, diffusing through 
the cells of the bacterial community to influence gene transcription and 
virulence factor production[115] .Three important interrelated quorum 
sensing systems are known designated the las, rhl and pseudomonas 
quinolone system[30]
.
 The molecular mediators of the quorum sensing are 
known as autoinducers (AI) .They have a role in regulation of gene 
transcription and virulence factor production which has been linked with 
PA01 chromosome in P.aeruginosa[45,119]. 
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TAXONOMY: 
The genus Pseudomonas and some closely related genera, many of 
which were formerly placed in the genus Pseudomonas, make up a group 
often referred to as the pseudomonads. The Pseudomonads are classified 
into 5 ribosomal RNA homology groups by Palleroni[97] based on rRNA-
DNA homology studies. On the other hand, Gilardi classified 
Pseudomonads into 7 major groups based on the phenotypic characters: 
fluorescent, stutzeri, alcaligenes, pseudomallei, acidovorans, facilis - 
delafieldi and diminuta[61]. 
Among the Pseudomonads, Pseudomonas aeruginosa is the well 
characterised and most frequently recovered Pseudomonad from clinical 
specimens. P.aeruginosa infection is especially prevalent among patients 
with burn wounds, acute leukaemia, cystic fibrosis, organ transplants and 
intravenous drug addiction [15]
. 
Infections with Pseudomonas usually occur at sites where moisture 
accumulates such as trachoestomies, indwelling catheters, burn wounds, 
the external ear (swimmer’s ear) and weeping ulcers [3].The exudation of 
bluish pus with a grape like odour from the production of  pyocyanin is  a 
characteristic feature of  Pseudomonas aeruginosa  infection. 
Individual cases of endocarditis, brain abscess, meningitis and bone and 
joint infections spreading through hematogenous route occur with regular 
23 
 
frequency in the literature [15].Puncture wounds through tennis shoes 
predispose to serious infections. Perinychia is associated with constant 
exoposure of extremities to water, detergents or mechanical stress. 
Pseudomonas aeruginosa also causes genito-urinary tract and lower 
respiratory tract infections; the later can be severe and life threatening in 
immunocompromised hosts. Sporadic Pseudomonas aeruginosa 
infections   following ear piercing have also been reported [56]
. 
 
MULTIDRUG RESISTANCE IN PSEUDOMONAS: 
Treatment of P.aeruginosa infection poses a therapeutic challenge 
for both nosocomial and community-acquired infections and selection of 
an appropriate antibiotic to initiate treatment is essential to optimize the 
clinical outcome [14]. A relatively narrow spectrum of antimicrobials is 
effective including the Carboxypenicillins, the Ureidopenicillins, the 
antipseudomonal Cephalosporin, Monobactams, Carbapenems, 
Quinolones and Aminoglycosides [35].  P. aeruginosa can develop 
resistance to antibiotics either through the acquisition of resistance genes 
on extrachromosomal mobile genetic elements (i.e., plasmids) [71] or 
through mutational mechanisms that alter the expression and or function 
of chromosomally mediated mechanisms. Both mechanisms for 
developing drug resistance can severely limit the therapeutic options 
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available. [68,94]. Although the availability of certain agents like 
Doripenem and fourth generation Cephalosporin, Cefipime provided the 
medical community with a certain degree of security, the situation has 
changed because of the selection strains of P. aeruginosa literally 
occurring worldwide, carrying the multiple resistant determinants that 
mediate β - lactam multiresistance along with resistance to  
Fluoroquinolone and Aminoglycoside group of drugs also [31]. Various 
definitions defining multi-drug resistant (MDR), extensively drug 
resistant (XDR) and pandrug-resistant bacteria, including P. aeruginosa 
have been recently reported [73]. 
 
MECHANISMS OF ANTIBIOTIC RESISTANCE  
AND BETA LACTAMASES 
Bacteria can express more than one mechanism of antibiotic 
resistance leading to MDR phenotypes or even pandrug resistance. 
Molecular analysis of P. aeruginosa isolates from a nosocomial outbreak 
revealed the convergence of several strategies for antibiotic resistance .1) 
Over expression of Amp C chromosomal β - lactamases conferring 
resistance to multiple β lactams [71]. 2) Mutational porin loss of OPr D 
porin, coferring resistance to Imipenem[70]
.
 3) Upregulation of  the Mex 
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XY efflux system[58] which exports Fluoroquinolones, Tetracyclines, 
Aminoglycosides and antipseudomonal β lactam agents.
 
P. aeruginosa carries multiple genetically based resistance 
determinants, which may act independently or in concert with           
others [71]
.
Among those of greatest concern are the chromosomal β - 
lactamases. 
BETA LACTAMASES - CLASSIFICATION 
β – lactamases are classes of enzymes that inactivate β - lactam 
antibiotics by splitting the amide bond of the β-lactam ring. They are 
mediated either by chromosomal genes or by transferrable genes located 
on plasmids and transposons. In addition, β – lactamases genes bla 
frequently reside on the integrons, which often carry multiple resistant 
determinants. 
β – lactamases can be classified  according to the amino acid 
structure into 4 molecular classes, A to D, as first suggested by Ambler 
[2]
. Alternatively, the Bush- Jacoby-Medeiros system classified the 
enzymes into several functional groups according to the substrate profile 
and susceptibility to β – lactamase inhibitors such as clavulanic           
acid [17].Class A, C and D β – lactamases hydrolyze the β-lactam ring 
through a serine residue at their active site, whereas class B enzymes are 
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metallo-β-lactamases that use zinc (zn2+) to break the amide bond.  
Table.1 and Table.2 show the classification of   β – lactamases. 
 
Table.1 Ambler molecular classification of β – lactamases 
  
     
CLASS                               
 
ACTIVE 
SITE
 
ENZYME TYPE 
 
SUBSTRATES 
 
EXAMPLES 
     A 
  
SERINE a)Broad spectrum       
Penicillinases 
 
 
b)ESBL 
 
 
 
 
 
c)Carbapenemases 
Benzyl penicillin 
Aminopenicillins 
Carboxy penicillins 
Ureidopenicillins 
 
 Narrow spectrum   
Cephalosporins 
Substrates of broad 
spectrum plus 
oyimino-β-lactams 
 
 
Substrates of 
Extended spectrum 
plus Cephamycins & 
Carbapenems 
PC1 in S.aureus 
TEM-1, SHV-1in E.coli, 
K.pneumoniae 
and other gram negative 
bacteria  
In enterobacteriaceae: 
TEM-Derived,SHV-
Derived,CTX-M-
Derived, PER-1,VEB-
1,VEB-2, GES-1, GES-2, 
IBC-2 in Pseudomonas 
aeruginosa 
KPC-1,KPC-2,KPC-3 in 
K.pneumoniae 
      B Metallo-β-
lactamases 
Carbapenemases Substrates of 
Extended spectrum 
plus cephamycins & 
Carbapenems 
IMP,VIM,GIM,SPM, 
SIM lineages in 
P.aeruginosa, 
Acinetobacter spp., 
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      C SERINE Cephalosporinases Substrates of 
Extended spectrum 
plus cephamycins 
Amp C type enzymes in 
Enterobacteriaceae, 
Acinetobacter baumanni 
 
 
     D SERINE Oxacillinases 
a)Broad spectrum 
 
 
 
 
 
b)Extended 
spectrum 
 
 
 
 
 
Carbapenemases 
 
 
Aminopenicillins, 
Ureidopenicillins, 
Cloxacillin, 
Methicillin, 
Oxacillin & some      
narrow spectrum 
Cephalosporins 
 
Substrates of 
Extended spectrum 
plus oxyimino-β-
lactams and 
monobactams 
 
 
Substrates of 
Extended spectrum 
plus Cephamycins 
and carbapenems 
 
OXA - family  in 
P.aeruginosa 
 
 
 
 
 
 
OXA derived in 
P.aeruginosa 
 
 
 
 
 
OXA derived in 
Acinetobacter spp., 
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Table.2 Bush-Jacoby–Medeiros Functional Classification scheme for 
β – lactamases 
Group Enzyme Type Inhibition by 
Clavulanate 
Molecular 
class 
Examples 
      1 Cephalosporinases    No     C Enterobacter cloacae 
p99(C),MIR-1(P) 
     2a 
     2b 
     2be 
     2br 
     2c 
     2d 
     2e 
     2f 
Penicillinase 
Broad spectrum 
Extended spectrum 
Inhibitor resistant 
Carbenicillinase 
Cloxacillinase 
Cephalosporinase 
Carbapenemase 
 
   Yes 
   Yes 
   Yes 
  Diminished 
   Yes 
   Yes 
   Yes 
    Yes 
 
    A 
    A 
    A 
    A 
    A 
  D/A 
    A 
    A 
Bacilluscereus, S.aureus(B) 
 
TEM-1(P),TEM 1(B) 
 
K.oxytocaK1(C),TEM3(P) 
TEM-30(IRT-2)(P) 
 
AER-1(C),PSE-1(P) 
Streptomyces caccoi (C) 
 
 
OXA-1(P), FEC-1(P) 
 
IMI-1(C), NMC-A(C) 
     3 Carbapenemase 
 
    No     B  Stenotrophomonas 
maltophila L1(C),IMP-1 
    4 Penicillinase 
 
    No     A Burkholderia 
cepacia,SAR-2(P) 
 
Note: B - both chromosomal and plasmid, C- chromosomal, P-plasmid. 
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EMERGENCE OF NEWER   BETA LACTAMASES – ESBLs,  
Amp C and MBLs 
The first report on ESBLs appeared in 1983[57], followed in 1988 
by reports of AmpC β-lactamases [13]
. 
ESBLs were first found in Europe, 
most commonly in isolates of klebsiella spp.,less commonly in E.coli 
[105]
.
The number of enzymes continue to increase[51]
.
These enzymes have  
been demonstrated in Enterobacteriaceae and more recently in other 
genera such as  P. aeruginosa [134]
.
 PER-1 was the first detected and fully 
characterized ESBL in P. aeruginosa. It was identified in 1991 in France 
from the urine culture of a Turkish citizen (Nordmann & Naas, 1994) 
which was encoded in chromosome. Later, plasmid mediated PER-1 
enzymes were also reported (Nordmann & Guibert, 1998).ESBLs confer 
resistance to all β lactams with the major exception of Carbapenems, such 
as Imipenem and are inhibited by Clavulanic acid. 
Plasmid-mediated AmpC β-lactamases have been identified in 
Klebsiella pneumoniae, Proteus mirabilis, Salmonella spp. and E. coli 
and were first documented in 1988 [13]. AmpC β - lactamases are 
cephalosporinases that inhibit Cephamycins as well as other extended-
spectrum Cephalosporins and are poorly inhibited by Clavulanic acid. 
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METALLO-BETA LACTAMASES  
          Metallo-β-lactamases are class B β lactamases, which requires 
divalent cations of zinc as cofactors for enzyme activity and are therefore 
inhibited by metal chelators. They have potent inhibitory activity not only 
against Carbapenems but also against other β - lactam antibiotics. 
Carbapenems, especially Meropenem, Imipenem, and Panipenem 
(available in Japan only) are potent drugs for the treatment of infections 
due to multidrug resistant P.aeruginosa. However, the prevalence of 
Carbapenem resistant P.aeruginosa strains has been increasing 
worldwide. The IMP and VIM genes are horizontally transferable via 
plasmids and can rapidly spread to other bacteria and are responsible for 
MBL production. Thus, MBL- producing P.aeruginosa strains have been 
reported to be important causes of nosocomial infections which are 
associated with clonal spread. 
Watanabe et al., 1991 [133] first reported pseudomonas aeruginosa 
producing MBLs from Japan in 1991 and Yan et al., 2001[137] and 
Yatsuyangai et al., 2004[139] documented the reports from various parts of 
world including Asia. 
Luzzaroa et al., 2004[72] described the 5 different types of MBLs 
whose prevalence is increasing rapidly as, IMP (Imipenem hydrolyzing 
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β-lactamase), VIM (Verona Integron encoded Metallo-β-lactamase), 
SPM (Sao Paulo Metallo-β-lactamase), GIM (German Imipenemase) and 
SIM (Seoul Imipenemase). Senda et al., 1996[121] stated that IMP and 
VIM are the most predominant MBLs so far. Lagatolla et al., 2004[63] 
described that new subtypes of IMP and VIM are being reported 
commonly and recently 11 subtypes of VIM and 21 subtypes of IMP have 
also been documented. Lauretti et al., 2004[64], Lee et el., 2005[66] pointed 
out that MBL producing Gram negative bacteria often are resistant to 
additional classes of drugs and behave as multi-drug resistant bacteria. 
Nordman et al., 2002[92] stated that the Gram negative bacteria producing 
acquired MBLs have been reported under standard conditions and are 
difficult to recognize. 
Lagotta et al., 2004[63], Libisch et al., 2004[69], Patzer et al.,2001[100], 
Poirel et al., 2000[110] documented the reports of MBLs from Europe, 
Peleg et al.,2004[101] from Australia, Gales et al., [36] from South America 
and Toleman et al.,2004[129] from North America. Bandoh et al., 1992[11] 
reported the transferrable MBLs in Bacteriodes Fragilis. Yong et al., [140] 
documented that apart from P.aeruginosa, other bacteria like Serratia, 
Klebsiella pneumoniae, Enterobacter aerogenes, E.cloacae, Proteus 
vulgaris,  Citrobacter freundii, P.putida, Acinetobacter and Alcaligenes 
xylosoxidans were also shown to produce MBL. Galleni et al., 2001[37] and 
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Garau et al.,[38]  proposed a standard numbering scheme and identified 
three subclasses of class B β – lactamases [B 1 to B 3]. 
Nordman and poirel et al., 2002 [92] and Walsh et al., 2005 [131] 
described that class B or the metallo - enzymes (MBL) are the most 
significant Carbepenemases. Over the last decade MBL producing 
isolates have emerged particularly in Pseudomonas aeruginosa. Bashir et 
al., 2011[12], Pitout et al., 2007 [108] described that MBL genes have spread 
from P.aeruginosa to Enterobacteriaceae in recent years, and a clinical 
scenario is developing that could indicate the global spread. Marr et al., 
2006 [79] described the fatal outcome when patients with serious MBL 
producing organisms are treated with antibiotics to which the organism is 
totally resistant. 
Hirakata et al 1998 [47] studied that Carbepenam - resistant Gram 
negative bacterial infections with Pseudomonas aeruginosa and Serratia 
marcescens have emerged in Japan, and these isolates are commonly 
producing  IMP -1 metallo-β-lactamase. Arakawa et al., 1995 [7] identified 
the bla IMP genes responsible for the IMP -1 production are usually 
mediated by integrons which are carried by transferrable plasmids. 
Senda.k., and Y.Arakawa et al., 1996[121] reported the transmissions of the 
bla IMP  gene cassette among various Gram-negative rods. Bush.k.1998 
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emphasized the importance of early recognition of IMP-1 producers are 
important for infection control, as they demonstrate a wide range of 
resistance to various broad spectrum β lactam antibiotics. Wood ford.N.et 
al.,1998[135] reported the world wide spread of several metallo - β- 
lactamase producing Gram Negative bacteria outside Japan such as 
United Kingdom, Italy and Singapore. After being primarily detected in 
P.aeruginosa, MBL was found in other Gram negative bacteria also, as 
described by Anne Marie Qeennan et al., 2007 [5]. 
Although various MBL detection techniques have been 
investigated, there are so far no gold standards or reference phenotypic 
methods for the detection of all transferrable MBLs [77]. Gupta et al., 
2006[42] documented a high prevalence of nosocomial infections due to 
P.aeruginosa. According to Navneeth BV et al
.,
[90]
.Gupta V, Datta et al 
2006[43] ,Jesudason MV et al.,2005[52] , Agarwal VA et al., and Mendiratta 
DK et al.,2005[84], production of MBL in P.aeruginosa are varying from 
7% - 65%. In India, Zavascki et al., 2006[143], Variya et al., 2008[130] and 
Hirakata et al., 1998[47] showed the prevalence of MBL from 8-
14%.Behera et al., 2008[9] stated that either MBL genes are not always 
expressed or resistance may require uptake of Carbapenems. With the 
emergence of Carbapenem susceptible MBL carrying organisms, the 
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decision of which isolates to be chosen for phenotypic MBL detection is 
controversial. Gibb A.P.et al 2002[39] reported an outbreak of IMP-7 
producing P.aeruginosa and also documented that bla VIM have replaced 
those producing IMP-7 recently. 
M.J.Carvalho et al., 2005[19] reported a new VIM-2 type MBL in 
P.aeruginosa in a portuguese hospital. Mazzoriol.A et al., 2005[81] 
detected a new VIM-11 type MBL in a clinical isolate of P.aeruginosa 
from Italy. Pena et al., 2005[103] studied the occurrence of metallo-β-
lactamase VIM-2 in P.aeruginosa isolates resistant to carbapenems in 
central Portugal. Bashir et al., 2011[12] documented 13.42% of 
P.aeruginosa were resistant to Imipenem and 11.66% were found to be 
producing  MBL and also documented that the interval between 
admission to hospital and isolation of pathogen was longer in patients 
infected with MBL producers than MBL non-producers. 
Elias et al., 2009[29] reported the nosocomial outbreak caused by a 
bla VIM-2 positive P.aeruginosa in patients of urology department of the 
University hospital, Wurzburg. Livermore and Woodford et al., 2000[71] 
proved that the prolonged hospital stay and prolonged use of antibiotics 
(especially Carbapenems) are the main risk factors for the emergence of 
the MBL producing  Gram negative organisms. 
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Debasrita Chakraborthy et al.,2010[26] studied the prevalence of 
MBL in gram negative infections from ICU in Kolkata and reported 31% 
of MBL producers from COPD patients and 10.5% from hepatic failure, 
cancer and cardiac disease patients and 21% were suffering from 
pneumonia. Supriya Upadhyay et al., 2010[128] studied the different beta 
lactamase classes among clinical Pseudomonas aeruginosa and reported 
46.6% as MBL producers among Amp C producing isolates. 
Ozgumus et al., 2007[95] studied the molecular epidemiology of 
Pseudomonas aeruginosa isolates carrying IMP-1 gene in a university 
hospital in Turkey. Noyal et al., 2009[93] found that 50% of resistance in 
Carbapenems among P.aeruginosa was due to the production of MBLs. 
But Jesudason et al., 2005[52] has documented MBL production   among 
75% of Imipenem resistant Pseudomonas isolates. 
Hirakata et al., 2003 [46] inferred from a study conducted in Japan 
that patients infected with MBL - producing P.aeruginosa  were treated 
with multiple antibiotics and more importantly, that infection related 
deaths due to MBL-producing  P.aeruginosa were more frequent than 
deaths caused by P.aeruginosa which were not producing  MBLs. 
Horieh Saderi et al., 2008[49] observed a resistance of 73.44 % to 
Ceftazidime among the P.aeruginosa and 53.2 % of screened isolates 
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were MBL positive. Another study from South India by Navaneeth et a l., 
2002[90] reported 12 % MBL-mediated Imipenem resistance in 
P.aeruginosa. Mihani et al., 2007[86] reported that 19.51% of Imipenem 
resistant P.aeruginosa   strains isolated from burned patients were MBL 
producers. 
Peleg et al., 2005 [102] described the MBL related outbreaks due to 
treatment of infection with Carbapenems caused by Carbapenem-
sensitive MBLs carrying hidden genes which involve in horizontal 
MBL gene transfer with other gram negative pathogens. 
Yoshichika et al., 2000[142] evaluated a simple test for screening 
MBL producing Gram Negative bacteria by using various MBL inhibitors 
including thiol compounds CuCl2, FeCl2,EDTA and thiol compounds like 
2-Mercaptopropionic acid, Mercaptoacetic acid, and Mercaptoethanol and 
tested for IMP-1 inhibition and used Cefazidime resistant strains to 
confirm the presence of the bla IMP  gene. Soo -Young kim et al., 2007[125] 
performed a study to evaluate the double disc tests involving discs 
containing Meropenem,  Imipenem, Ertapenem and Ceftazidime; discs 
containing  high and low concentrations of Tris - EDTA ,discs containing 
2-Mercaptopropionic acid [MPA]; and TE discs supplemented with MPA 
for the detection of MBLs. In their study, they concluded that by using 
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IPM and TE disc supplemented with 20 µl of 1:320 MPA, the MBL 
producers can be detected accurately. Arakawa et al., 2000[7], inferred 
that Ceftazidime discs used along with MPA provided accurate MBL 
detection because MBL producing organisms were usually highly 
resistant to CAZ. 
Yong et al., 2002[140]  used IPM-EDTA disc method, with 750µg of 
EDTA in combination with IPM discs with a zone difference of  ≥ 7 mm 
between IPM alone and along with EDTA as the criterion to detect 
MBLs. They obtained excellent sensitivity and specificity to detect VIM-
2 type and IMP-1 type producing P.aeruginosa and Acinetobacter spp. In 
a study conducted by Agrawal et al.,2008[1],  Polymyxin B was most 
effective antibiotic with 0% resistance similar to the reports of Sarkar et 
al.,2006[117] followed by Imipenem (8.05%) and Ceftazidime (10.35%).In 
the Studies of Shahid et al.,2004[122]  and Pitt et al.,2003[109] Ceftazidime  
resistance was 20% and 39.6% respectively. 
Johann D.D Pitout et al., 2005[54] inferred that Meropenem alone 
and along with EDTA showed 100% sensitivity and 97% specificity in 
identifying MBL producing strains of P.aeruginosa and gave good results 
than Imipenem and the MBL E test. They also performed Duplex PCR 
assay with excellent sensitivity & Specificity for the simultaneous 
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confirmation of VIM & IMP genes in Pseudomonas aeruginosa. 
Genotypic methods of detection of MBL producing organisms give 
specific and accurate results, but due to cost constraints, it is of limited 
use in all laboratories [53]. 
Clare Franklin et al 2006 [20] performed the phenotypic detection of 
Carbapenem sensitive MBL producing gram negative bacilli by using 
double disc synergy test and a combined disc test with Imipenem and 292 
µg of  EDTA on one agar plate. They also inferred that out of the 84 
MBL carrying isolates 51 were sensitive to atleast one carbapenem. Yan 
et al., 2004 [138]
 
also studied on the detection of Carbapenem sensitive 
MBL carrying organisms and compared three methods, the double disc, 
combined disc and the E test. 
Walsh et al.,2002 [132] while evaluating the MBL E test inferred that 
both Mueller-Hinton Agar and Isosensitest media had excellent 
sensitivity, 97% for Mueller-Hinton agar & 93% for Isosensitest agar. 
M.J.C. Noyal et al., 2009[93] evaluated simple screening methods for 
detection of carbapenemases in non-fermentative Gram negative bacilli 
and inferred that disc synergy test using EDTA as a better method for 
detecting MBLs than Modified Hodge test. Rizvi et al., 2009[116] also 
inferred that disc synergy test using EDTA as a better method for 
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detecting MBLs than Modified Hodge test. Andrade et al., 2003 [4] has 
reported that resistance to Carbapenems in P.aeruginosa has increased to 
40%. Kanungo et al., 2006[55] inferred from  a study done at a  tertiary 
care centre in Puducherry, India, 10.9% resistance with Carbapenems in 
P.aeruginosa isolates . Mahendralingam et al., 1996[74] attempted plasmid 
extraction from all Imipenem and Ceftazidime resistant isolates by 
alkaline lysis method.  
Hemalatha et al., 2005[44] found that Ceftazidime - EDTA could 
pick up additional isolates of MBL producers than than with Imipenem- 
EDTA. Bashir et al., 2011[12] compared three different methods for 
identifying MBL producing P.aeruginosa; combined disc test, reduction 
in MIC with Imipenem plus EDTA combination and E-test. In their study 
13.42% of the isolates were resistant to Imipenem and 11.66% were 
found to be MBL producer by combined disc test and showed zone 
enhancement of ≥ 7 mm around both Imipenem- EDTA disc and 
Ceftazidime - EDTA disc compared to plain discs. 
In 1996, a PCR detection assay was published for the detection of 
Gram negative bacilli producing IMP-1type MBLs by Senda et al., [121] 
and a PCR typing scheme for detection of integron associated MBLs was 
published in 2003 by Shibata et al., [123]. Confirmation of MBLs with 
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PCR is an important step, since EDTA can give false positive results in 
due to altered Opr D levels as described by Conejo et al 2003 [23]. Pitout et 
al.,2005 [108],developed a duplex PCR assay with excellent sensitivity and 
specificity for the simultaneous confirmation of IMP and VIM genes in 
MBL producing Pseudomonas aeruginosa , whereas PCR typing method 
was proposed by Shibata et al., in 2003 [123] involves sequencing of the 
amplicons. 
          The identification of MBL and other Carbapenemases is of prime 
importance in choosing the most appropriate antibiotic for the treatment 
of Carbapenem resistant isolates in any health care set up. The severity of 
Pseudomonas aeruginosa infection can be decreased by early and prompt 
detection and appropriate treatment before the bacteria change to a 
mucoid phenotype, which is extremely difficult to eradicate if once 
established.  
           Common antipseudomonal drugs are Carbenecillin, Ceftazidine, 
Piperacillin-Tazobactam & Cefoperazone – Sulbactam. The Carbapenems 
are one of the last resorts for the treatment of serious multi-drug resistant 
Pseudomonas aeruginosa infection. Meropenem, Ertapenem and 
Imipenem/Cilastin are effective against most ESBL and AmpC producing 
organisms. Though these novel carbapenems are more effective against 
Multi Drug Resistant Pseudomonas infections, resistance is still mediated 
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through OprD deletions and spread of broad-spectrum Carbapenemases 
and MBLs. In studies conducted by Walsh et al., 2005[135], intravenous 
Colistin with Rifampin and Imipenem was suggested for the treatment of 
Carbapenem resistant isolates without MBL production, whereas the 
combination of Colistin and Rifampicin with or without Tigecycline was 
suggested for treatment of MBL producing Carbapenem resistant isolates 
as described by Maragakis LL et al., 2008 [78] and Perez et al., 2007 [105]
. 
The medical community has now started  to use  drugs like Colistin 
and Polymyxin B which were once not used decades ago due to their 
toxicity but are now being considered as ‘‘antimicrobials for the 21st 
century’’ [85]. However some researchers reported emergence of Colistin 
resistant organisms in their study [6], which necessitates the discovery of 
newer molecules to treat the patients earlier and prevent the development 
and dissemination of resistance in the future. 
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MATERIALS   AND   METHODS 
 
            It is a prospective study conducted in patients admitted to 
Government Rajaji Hospital, attached to Madurai Medical College, 
Madurai. The study was conducted between June 2011 & May 2012. 
Ethical committee clearance has been obtained from the institution and 
written informed consent received from the patients before collecting the 
specimens. A total of 580 clinical samples were collected including pus, 
sputum, urine, blood, ascitic fluid, endotracheal fluid, broncho-alveolar 
lavage and wound swab from the patients who were admitted to various 
clinical departments of Govt. Rajaji Hospital, Madurai. 
Inclusion Criteria: 
• Males and females of all age groups were included 
• Patients affected with burn wounds, Patients with non-healing ulcer 
• Diabetic patients with ulcers 
• Patients with provisional diagnosis of Septicaemia and Pneumonia  
• Patients with indwelling urinary catheter 
• Patients on ventilatory support for prolonged period in IRCU  
• Patients with peritonitis 
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COLLECTION OF SPECIMENS 
 Collection of Blood sample: 
Blood samples were collected by strict aseptic technique. The skin 
over the vene puncture site approximately 5cm diameter was 
cleansed thoroughly with 70 % ethanol followed by povidone 
iodine and allowed to dry at least for one minute before collecting 
the sample. 5 ml of blood was collected in 50 ml of Brain Heart 
Infusion Broth (B.H.I) in adults. In the paediatric age group 1 to 2 
ml of blood was collected in appropriate quantity of B.H.I. 
 Collection of Pus sample: 
Sterile cotton wool swabs were used to collect the sample from 
infected sites. The swabs were transported in sterile test tubes to 
the laboratory. Two swabs were collected from patients and 
subjected to direct smear and culture. Sterile disposable syringe 
was used to aspirate pus in case of abscesses.  
 Collection of Sputum sample: 
The patients were asked to cough deeply before collecting the 
sputum to avoid mixing of saliva with the sputum. It was collected 
in the morning before any mouthwash was used and mouth should 
be rinsed with saline or water just before expectoration. Clean, dry, 
44 
 
sterile wide mouthed, properly labeled, screw capped and leak 
proof containers were used for sputum collection. 
 Collection of Urine sample: 
Patients were instructed for proper collection of urine samples 
without any contamination. Male patients were asked to retract the 
prepuce and clean the urethral meatus with saline and to collect the 
early morning, mid stream urine. Female patients were asked to 
clean the genitals with soap and water and to dry the area with 
sterile gauze pad. The urine was collected with the labia held apart. 
The specimen was collected in a clean, wide mouthed, screw 
capped and leak proof container and transported to the laboratory 
without any delay. 
 Collection of wound swab: 
In cases of burn wounds and diabetic patients with ulcers, the 
wound site was cleaned with sterile saline and before application of 
any topical antibiotic preparation, two swabs were taken with 
sterile cotton swabs from the edge of the wound with active 
infection. The swabs were moistened with sterile saline before 
collecting the specimen to avoid drying of the specimen before 
processing.      
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  Collection of Endotracheal aspirate:       
In patients with tracheostomies, who were unable to produce 
sputum, the endotracheal secretions were collected by aspirating 
the fluid by suctioning. The specimen was collected in a sterile 
container and transported immediately to the laboratory                 
 Collection of  Bronchoalveolar – Lavage(BAL): 
Bronchoscopy assisted bronchial washings or aspirates were 
obtained by instilling a small amount of sterile physiological saline 
into the bronchial tree and by withdrawing the fluid. The specimen 
was collected in a sterile container and transported immediately to 
the laboratory. 
 Collection of ascitic fluid: 
The skin over the site of collection was sterilized with 70% alcohol 
and atleast 10 ml of fluid was aspirated with sterile syringe and 
needle and collected in a sterile tube or vial and transported to the 
laboratory.  
 The collected specimens were properly labeled with Name, Age, 
Sex, I.P/ O.P.No. of the patient, Date and Time of collection, Type 
of sample and Name of the ward and brought to the laboratory and 
processed immediately. 
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PROCESSING OF SAMPLES: 
Blood: BHI broth containing blood samples were kept in the incubator at  
37˚Cfor 18-24hours after which the broth which showed turbidity was  
subcultured onto the following media using sterile technique. 
1. Nutrient Agar 
2. MacConkey Agar 
3. Blood Agar 
The broths which were clear were kept for further incubation and 
regarded as negative for growth if it appeared clear even after 48 hours of 
incubation. 
Urine: The urine specimens were centrifuged at 500-1000 g for 5 
minutes. The sediment was used for wet mount and if bacteria and pus 
cells were seen direct Gram staining was done and the supernatant was 
used for inoculating into culture media and incubation was done at 37˚C 
for 18-24 hours aerobically. 
Wound swab: One swab was used for direct Gram staining and the other 
swab used for inoculating into solid culture media and incubation was 
done at 37˚C for a period of 18-24 hours aerobically. After this initial 
processing the swabs were kept in glucose broth and after overnight 
incubation the glucose broth was observed for turbidity and if the culture 
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plates showed no growth after overnight incubation a repeat subculture 
was done from the glucose broth which contained the swabs. 
Pus, Sputum, Endotracheal fuid, Ascitic fluid and BAL: The 
specimens were processed, first by doing direct Gram staining and then 
inoculating into culture media and incubation was done at 37˚C for a 
period of  18-24 hours aerobically. 
CULTURE IDENTIFICATION: 
After overnight incubation, the culture plates were examined for 
the presence of growth and the organisms were identified by morphology 
of colonies on solid media, Gram staining, biochemical reactions and 
other special identification tests. 
ISOLATION AND IDENTIFICATION OF PSEUDOMONAS 
AERUGINOSA: 
Identification was mainly based on the Gram staining, colony 
morphology on Nutrient Agar, MacConkey Agar and Blood Agar, the 
characteristic odour in culture plates, oxidase test, motility, biochemical 
reactions and growth at 42˚C. 
GRAM STAINING: From a single isolated colony on Nutrient agar 
plate, the smear was prepared in clean, dry, grease free slide and it was 
dried in air and fixed by heating. The smear was then flooded with 0.5% 
Methyl violet and washed with water after 1 minute. Gram’s Iodine was 
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added to the smear and washed with water after 1 minute. Then the smear 
was decolorized with one or two drops of Acetone and immediately 
washed with water. The counter stain, 1:10 dilute Carbol fuschin was 
added to the smear and washed with water after 1 minute. The smear was 
then dried with blotting paper and viewed under oil immersion objective. 
Pink colored bacilli arranged in discrete pattern were identified as Gram 
Negative Bacilli. 
COLONY MORPHOLOGY: Pseudomonas aeruginosa was identified 
based on the typical colony morphology in different culture media as 
follows: 
Nutrient agar: Green pigmented, smooth, large, low convex, translucent 
colonies with earthy, grape like or corn-taco like odour. 
MacConkey agar: Pale or colourless, Non-Lactose fermenting colonies 
with spreading edges. 
Blood agar: Beta hemolytic, Greyish white colonies with metallic sheen. 
MOTILITY (HANGING DROP METHOD): A clean cover slip was 
taken and paraffin was applied to all the four corners. A drop of broth 
culture was placed on the centre of the cover slip with the sterilized 
inoculating loop. The cavity slide was taken inverted over the cover slip 
with the drop so that the drop was placed in the centre. The slide was 
inverted and focused under 10x and the edge of the drop identified. Then, 
49 
 
without changing the field, the focus was shifted to 40x and observed for 
the motile organisms. Actively motile bacilli were seen which was 
supportive for the identification of P.aeruginosa. 
BIOCHEMICAL REACTIONS: With the following tests Pseudomonas 
aeruginosa was identified biochemically. 
Oxidase test (Disc method): The oxidase disc was moistened with 
normal saline and then the colony from nutrient agar was taken with the 
help of a sterile glass rod and applied over the disc. Deep blue or purple 
colour in 10 seconds was taken as positive test. 
Catalase test (Tube method): 2-3 ml of 3% Hydrogen peroxide was 
taken in a clean test tube. Few colonies of the test organism were taken 
from the culture plate with a sterile glass rod and immersed in the 
Hydrogen peroxide solution. Brisk effervescence within ten seconds was 
considered as catalase positive. 
TSI (Triple sugar iron medium): An isolated colony from the culture 
plate was taken with a straight wire loop and stabbed into the butt portion 
of the TSI medium, withdrawn and streaked in a zig-zag manner over the 
slant portion and incubation was done at 37˚Cfor 18-24 hours. The 
observation of alkaline change over the butt portion and alkaline change 
over slant portion was identified as a non-fermentor. 
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Citrate utilization test: The well isolated colony from the culture plate 
was taken with a straight wire loop and inoculated into the Simmon’s 
citrate medium and incubation was done at 37˚C for 18-24 hours. The 
colour change from green to blue colour or the growth of colonies on the 
streak line was considered as positive citrate utilization test. 
Oxidation-fermentation (O/F ) test : Two tubes of O.F medium 
containing glucose were inoculated with the organism isolated from 
Nutrient agar plate by stabbing 3-4 times half way to the bottom of the 
tube .One tube was promptly covered with a layer of sterile melted 
paraffin jelly to a depth of 5-10 mm, leaving the other tube open to the 
air. Both the tubes were kept in the incubator at 35˚C for 72 hours and 
examined daily. The formation of yellow colour (acid) in the open tube 
and green colour (alkaline) in the sealed tube indicated oxidative 
metabolism of the organism. 
Nitrate reduction test: The nitrate medium was inoculated with a loop 
full of the test organism isolated in pure culture on agar medium and 
incubation was done at 35˚C for 18-24 hours. At the end of incubation, 1 
ml of Nitrate A  (alpha - Naphthylamine and 5 N 30% Acetic acid) and 
Nitrate B (Sulphanilic acid and 5 N 30% Acetic acid) reagent were added 
in that order. The development of red colour within 30 seconds after 
adding the reagents indicated a positive nitrate reduction test. If no colour 
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developed after addition of reagents, zinc dust was added to confirm a 
true negative reaction. 
Growth at 42˚C: Two tubes of Trypticase soy agar (TSA) were 
inoculated by streaking over the slant portion with a light inoculum by 
touching a needle to the top of a single 24 hour old colony from nutrient 
agar plate. Incubation was done at 35˚C for one tube and the other at 
42˚C. Good growth at 35˚C and 42˚C after 24 hours of incubation was 
considered as positive test for Pseudomonas aeruginosa. 
Arginine dihydrolase test: A well isolated colony of the test organism 
previously recovered on primary isolation agar was taken and inoculated 
into two tubes of Moeller Decarboxylase medium, one containing 
arginine amino acid and the other tube was used as a control tube devoid 
of arginine. Both tubes were over layed with sterile mineral oil to cover 
about 1 cm of the surface and incubation was done at 35˚ c for 18-24 
hours. Conversion of the control tube to a yellow colour indicated that the 
organism was viable and reversion of the tube containing the amino acid 
to a blue purple colour indicated a positive test owing to the formation of 
amines from the decarboxylation reaction.  
Other biochemical tests done are:  Indole production, MR/VP test, 
Mannitol fermentation, Urea hydrolysis, Aesculin hydrolysis were all 
negative. 
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DETECTION OF METALLOBETALACTAMASE PRODUCTION 
IN PSEUDOMONAS AERUGINOSA BY PHENOTYPIC 
METHODS:      
           Antibiotic susceptibility testing was performed for all the 
Pseudomonas aeruginosa isolates as per the standard CLSI guidelines for 
the following antimicrobials by using Kirby- Bauer disc diffusion 
method. 
          Piperacillin (75µg), Piperacillin – Tazobactam (100/10µg), 
Gentamicin (10 µg), Amikacin (30 µg), Norfloxacin (10µg), 
Ciprofloxacin (5µg), Netilmicin (30µg), Ceftazidime (30µg), Ceftriaxone 
(30µg), Imipenem(10µg), Meropenem (10µg), Polymyxin B (300U). 
Kirby-Bauer’s disc diffusion method: 
       3-5 well isolated colonies were picked up and emulsified in 2 ml of 
nutrient broth and incubation was done at 37˚C of 2-4 hours. The 
turbidity of the inoculum was adjusted to 0.5 McFarland standard using 
Wickham’s chart. Using a sterile cotton swab that was soaked with the 
broth, a lawn culture was made onto the dried surface of Muller-Hinton 
agar (MHA). Excess broth was expressed by rotating the swab gently 
against the inner side of the tube. The plates were allowed to dry for 15 
minutes and the pre-determined panel of antibiotic discs were dispensed 
onto the inoculated MHA plate and incubation was done at 37˚C for 18-
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24 hours. The zone diameter was recorded and interpretation was done as 
sensitive, intermediate and resistant as per the CLSI guidelines 2011. 
MIC determination by agar dilution method: 
Preparation of media: 
Mueller- Hinton agar was prepared in tubes and autoclaved.  It was 
then allowed to cool in a 50oC water bath. Serial dilution of the 3 GCs 
Ceftazidime and Imipenem were prepared in sterile distilled water to give 
a final concentration ranging from 0.5µg – 2048µg/ml of agar. After 
adding the 1 ml of appropriate dilution of drug to the 14 ml of medium at 
55o C it was mixed well and poured into sterile petridishes. (The media 
was used immediately otherwise potency of drugs would be affected. 
Upto 12 different organisms can be inoculated in a single plate).A control 
plate containing the test medium without the antibiotic was prepared for 
each series of test. 
Inoculum Preparation:  
At least 3-5 well isolated colonies of the similar morphology were 
selected from an agar culture plate. Top of each colony was touched with 
a loop and then was transferred into a tube containing 4-5ml of broth and 
incubation was done at 37oC until it reaches 0.5 Mc Farland’s standard 
(usually 2-6 hrs). This results in growth corresponding to 150 million 
organisms /ml. 
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Inoculation of test plates:  
           Plates of various concentrations were divided into required number 
(9-12 divisions / plate).  10µl of inoculum was put into the appropriate 
quadrant and incubation was done at 37oC for 16-18 hours. Minimum 
inhibitory concentration for Imipenem and Ceftazidime was measured as 
the lowest concentration of drug at which no visible growth occurs for 
that particular strain.  
Screening and confirmation of MBLs: 
The Pseudomonas aeruginosa isolates which were found to be 
resistant to Ceftazidime, Imipenem and Meropenem by Kirby - Bauer 
disc diffusion method were selected and the minimum inhibitory 
concentration of resistant isolates were determined and subjected to 
various phenotypic detection methods such as Combined disc diffusion 
Test, Modified Hodge Test, Double Disc Synergy Test and E Test and 
confirmed by genotypic method i.e, PCR. ATCC 27853 Pseudomonas 
aeruginosa was used as a negative control. 
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Common initial steps – Inoculum preparation:  
1. 3-5 colonies of the strain to be tested were touched from 24 hour 
culture plate with a straight wire loop and transferred to sterile 
peptone water and incubation was done at 37˚C and turbidity 
adjusted  to 0.5 McFarland standard. 
2. A lawn culture was made on cation balanced Mueller Hinton agar  
plate with a sterile cotton swab using the inoculum.(Excess broth 
was expressed by rotating the swab against the inner side of the 
suspension  tube before inoculation) 
3. Inoculum was then allowed to dry for 3-5minutes but not more 
than 15 minutes before applying the antibiotic disc or E test strip. 
 
 Preparation of EDTA solution:  
0.5 M EDTA solution was prepared by dissolving 186.1g of 
disodium EDTA.2H2O in 1000 ml of distilled water and its pH was 
adjusted to 8.0 by using NaOH. The mixture was then sterilized by 
autoclaving. EDTA solution was added on Imipenem and 
Ceftazidime discs to obtain a desired concentration of 750 µg per 
disc.  
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Determination of MIC of Imipenem and ceftazidime with EDTA: 
1 ml of EDTA solution was added to solution containing 1 ml of 
Imipenem and Ceftazidime. 2 ml of EDTA solution with the corresponding 
drug was mixed with 18 ml of Mueller- Hinton agar. Inoculation and 
incubation of plates were done as described for MIC determination of the 
individual drugs without EDTA. The highest dilution which inhibited the 
growth of the organisms was taken as MIC of Imipenem/Ceftazidime plus 
EDTA combination and was compared to MIC of Imipenem/Ceftazidime 
alone. A minimum fourfold reduction in MIC with Imipenem/Ceftazidime 
plus EDTA combination when compared to the MIC of individual drugs 
alone was interpreted as being suggestive of MBL production. 
 
 Combined Disc Diffusion Test (CDDT): 
 The strain to be tested was inoculated onto MHA plate as 
suggested by the CLSI. Two Imipenem(10µg)  discs were placed 
on the plate and 10µl of 0.5 M EDTA solution was added to one of 
them to obtain the desired concentration (750µg).  
 After18 hours of incubation, the zone diameter of Imipenem and 
Imipenem EDTA discs were compared. The increase in inhibition 
zone with Imipenem with EDTA disc ≥5mm than the Imipenem 
disc alone was considered as MBL positive. 
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 Similarly the test was done with two Ceftazidime discs and zone 
enhancement of ≥5mm with EDTA was considered as positive.  
  
Double Disc Synergy Test (DDST): 
 Lawn culture of the test organism was prepared over Mueller-
Hinton agar plate as per CLSI guidelines. 
 A plain sterile disc was kept 10 - 20 mm apart from either a 
Ceftazidime(30µg) or Imipenem(10µg) disc. 
 5 µl of EDTA was added to plain disc and incubation was done at 
37˚C overnight. 
 Presence of an extended zone from Imipenem or Ceftazidime disc 
towards EDTA was interpreted as positive. 
   
 Modified Hodge Test (MHT):  
  ATCC E.coli 25922 inoculum was prepared in 0.5 Mc Farland 
standards & lawn culture was made on Mueller-Hinton agar plate. 
 Meropenem disc (10µg) was kept in the centre of the lawn. 
 Colonies of Meropenem or Ceftazidime resistant isolates were 
taken & inoculated from edge of the disc to edge of the plate in a 
straight line & incubation was done at 37° C over night. 
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  The formation of a clover leaf like indentation along the test 
strains indicated carbapenemase production. 
 
   MBL E test (Imipenem and Imipenem with EDTA): 
 E test is a predefined, stable gradient of antibiotic concentrations 
on a plastic strip. Using innovative dry chemistry technology, E 
test is used to determine the on-scale Minimum Inhibitory 
Concentration (MIC) of antibiotics, antifungal agents and anti-
mycobacterial agents. 
 E test MBL strip is a unique phenotypic detection strip which is 
coated with mixture of Imipenem + EDTA and Imipenem in a 
concentration gradient manner. The strip is made of porous 
material and the antibiotics are distributed evenly on either side of 
the strip. 
 E test MBL strip has a double sided antibiotic dilution range of 
Imipenem (4 to 256µg/ml) and Imipenem (1 to 64 µg/ml) in 
combination with a fixed concentration of EDTA. 
 Procedure: The inoculum for E test was prepared as for other tests 
as mentioned previously. A sterile cotton swab was soaked into 
standardised inoculum and the swab rotated and pressed firmly 
against the inside wall of the tube to express excess fluid. The 
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entire agar surface of the Mueller-Hinton agar plate was streaked 
with the swab three times by turning the plate at 60˚ angle between 
each streaking and allowed to dry for 15 minutes. The E test MBL 
strip container was removed from the cold and kept at room 
temperature for 15 minutes before opening .The strip was then 
taken with a sterile forceps and applied to the dried agar surface 
with the MIC scale facing upwards. The strip adsorbed within 60 
seconds to the agar surface and then incubation of plate was done 
at 37˚C for 24 hours and the results were interpreted. 
 Interpretation: The plates were read only after sufficient growth 
was seen. The value of MIC was read where the ellipse intersected 
the scale on the strip.MIC ratio of Imipenem to Imipenem + EDTA 
of >8, or reduction of Imipenem MIC by ≥ 3 Log 2 dilutions in the 
presence of EDTA or formation of a phantom zone indicated MBL 
production. 
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DETECTION OF MBL PRODUCTION IN PSEUDOMONAS  
AERUGINOSA BY GENOTYPIC METHOD - PCR 
IMP/ VIM Gene Assay 
Requirements: 
DNA purification kit,  PCR Master Mix, Agarose gel electrophoresis and 
Primers.  
2X PCR Master Mix:  
It contains 2U of Taq DNA polymerase, 10X Taq reaction buffer, 2mM 
MgCl2, 1µl of 10mM dNTPs mix and PCR additives. 
Agarose gel electrophoresis: 
Agarose, 50X TAE buffer, 6X gel loading buffer and Ethidium bromide.  
DNA extraction from P.aeruginosa isolates - Procedure: 
Genomic DNA extraction from bacterial pellet using PureFast Genomic 
DNA purification kit: 
1. Bacterial Pellet was suspended in 200µl of PBS. 
2. 50µl of Lysozyme [50mg/ml] was added and incubation was done at 
37ºC for 15min. 
3. Added 400µl of Lysis Buffer and 40µl of Proteinase K 
[Reconstituted] 
4. Mixed immediately by inverting and incubation was done at 70ºC 
for 10min. 
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5. Added 100µl of Isopropanol and mixed well. 
6. Pipetted entire sample into the PureFast® spin column. Centrifuged 
at 13,000 rpm for 1 min. The flow-through was discarded and the 
column was placed back into the same collection tube. 
7. 500µl Wash Buffer-I was added to the PureFast® spin column. 
Centrifuged at 13,000 rpm for 30-60 seconds and discarded the 
flow-through. Placed the column back into the same collection tube. 
8. Added 750µl Wash Buffer-II to the PureFast® spin column. 
Centrifuged at 13,000 rpm for 30-60 seconds and discarded the 
flow-through. Placed the column back into the same collection tube.   
9. Repeated Step 8 once. 
10. Discarded the flow-through and centrifuged at 13,000 rpm for an 
additional 1 min. This step was essential to avoid residual ethanol. 
11. Transferred the PureFast® spin column into a fresh 1.5 ml micro 
centrifuge tube. 
12. Added 100µl of the pre-warmed Elution Buffer to the PureFast® 
spin column.  
13. Incubation was done for 2 min at room temperature and centrifuged 
at 13,000 rpm for 2 min.   
14. Discarded the column and stored the purified DNA at -20°C.  For 
gel analysis, loaded 10 - 20µl of elute. 
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PCR Procedure: 
Primer Sequence: 
IMP gene primer 
Product size = 220bp 
Forward Primer-   5'-TTTTGCAGCATTGCTACCGC-3' 
Reverse primer-    5'-CACGCTCCACAAACCAAGTG-3' 
VIM gene primer 
Product size = 442bp 
Forward Primer -   5'-GTGCTTTGACAACGTTCGCT-3' 
Reverse primer -   5'-TCCACGCACTTTCATGACGA-3' 
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1. Reactions set up as follows; 
VIM Setup: 
Components Quantity 
In PCR vial 
    Master mix 
25µl 
VIM Primer Mix      (10pmoles/µl) 1µl 
Genomic DNA 1µl 
Water, nuclease free 23µl 
Total volume 50µl 
 
 
 
IMP Setup: 
Components Quantity 
In PCR vial 
    Master mix 
25µl 
IMP Primer Mix      (10pmoles/µl) 1µl 
Genomic DNA 1µl 
Water, nuclease free 23µl 
Total volume 50µl 
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2. Mixed gently and spinned down briefly. 
3. Placed into PCR thermocycler and programmed as follows; 
Initial Denaturation: 94ºC for 3 min 
Denaturation: 94ºC for 1 min 
Annealing:      58ºC for 1min                  30 cycles 
Extension:       72ºC for 1min 
Final extension: 72º C for 5 min 
Agarose gel electrophoresis: 
1. Prepared 2% agarose.  (2gm agarose in 100ml of 1X TAE buffer and 
melted using micro oven). 
2. When the agarose gel temperature was around 60ºC, 5µl of Ethidium 
bromide was added. 
3. Poured warm agarose solution slowly into the gel platform.   
4. Kept the gel set undisturbed till the agarose solidified. 
5. Poured 1XTAE buffer into submarine gel tank. 
6. Carefully placed the gel platform into tank.  Maintained the tank 
buffer level 0.5cm above the gel. 
7. Templates were loaded after mixing with gel loading dye along with 
10µl HELINI 100bp DNA Ladder. 
8. Run electrophoresis at 50V till the dye reaches three fourth distance 
of the gel. 
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9. Gel viewed in UV Transilluminator and observed the bands pattern.  
 
Interpretation: The presence of IMP and VIM gene was indicated by the 
amplification of   220 & 442   base pairs PCR product from the clinical 
isolates respectively. 
The various phenotypic methods were compared with PCR and 
sensitivity, specificity, PPV and NPV were determined. The P value and 
95% confidence intervals were obtained using SPSS (Stastical Package 
for Social Sciences) version 16. P value <0.05 was taken as significant 
and P value >0.05 indicates that there is no significant difference between 
the various tests compared and PCR. 
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RESULTS 
 
A total of 580 clinical samples of pus, sputum, urine, blood, ascitic 
fluid, endotracheal fluid, broncho-alveolar lavage and wound swab 
collected from the patients admitted to various clinical departments of 
Govt.Rajaji Hospital Madurai were processed and the results are shown 
in Table no.1. 
Table 1. Specimen wise isolation of organisms    n=580 
 
Specimen P.aeruginosa 
Other Gram 
negative 
bacilli 
Gram 
positive 
cocci 
No growth Total 
Pus 33(5.68%) 32(5.51%) 90(15.51%) 20(3.44%) 175(30.17%) 
Wound 
swab 
24(4.13%) 48(8.27%) 30(5.17%) 12(2.06%) 114(19.65%) 
Sputum 20(3.44%) 22(3.79%) 18(3.10%) - 60(10.34%) 
Urine 18(3.10%) 70(12.06%) 10(1.72%) 23(3.96%) 121(20.86%) 
Blood 7(1.20%) 17(2.93%) 52(8.96%) 12(2.06%) 88(15.17%) 
Body 
fluids 
6(1.03%) 13(2.29%) - 3(0.51%) 22(3.79%) 
Total 108(18.62%) 202(34.82%) 200(34.08%) 70(12.06%) 580 
 
Out of the 580 clinical samples, 175 samples were pus, 114 
samples were wound swab, 121 samples were urine, 60 samples were 
sputum,88 samples were  blood and 22 samples were body fluids.70 
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samples showed no growth and 510 showed growth. Among the 510 
isolates, 108 were Pseudomonas aeruginosa, 202were Gram negative 
bacilli other than Pseudomonas, 200 were Gram positive cocci. The 
analysis of specimen wise, age wise and sex wise distribution of 
Pseudomonas aeruginosa was done and given in Table no. 2, 3 & 4.      
 
Table2. Specimen wise isolation of Pseudomonas aeruginosa   
                                                                                             n =108 
Specimen 
No. of Pseudomonas 
aeruginosa isolates 
Percentage (%) 
Pus 33 30.5 
Wound Swab 24 22.2 
Sputum 20 18.5 
Urine 18 16.6 
Blood 7 6.4 
Body fluids  6 5.5 
 
  Among the 108 Pseudomonas aeruginosa isolates, 33 were from 
pus, 24 from wound swab, 20 from sputum, 18 from urine, 7 from blood 
and 6 from body fluids. 
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Table3. Age wise distribution of P.aeruginosa   n =108 
 
 
                                       
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
 
 
 
 
 
 
 
Age wise distribution of Pseudomonas aeruginosa was analysed which 
showed 1 isolate was from less than 1 year of age, 12 were from 1-10 years age 
group, 9 from 11-20 years age group, 19 from 21-30 years age group, 20 from 31-
40 years age group, 21from 41-50 years age group13 from 51-60 years age group, 
and 13 from >60 years age group.  
 
 
 
 
Age in years Number of patients Percentage (%) 
< 1 1 0.92 
1-10 12 11.1 
11-20 9 8.33 
21-30 19 17.59 
31-40 20 18.51 
41-50 21 19.44 
51-60 13 12.03 
>60 13 12.03 
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Table4. Sex distribution of P.aeruginosa       n=108 
Male 
 
Female` 
 
61(56%) 
 
47(44%) 
 
 
Out of the 108 isolates of P.aeruginosa, 61were isolated from males and 
47 were isolated from females.   
 
Table5.  Risk factors associated with P.aeruginosa       n = 108 
 
Risk factors 
No. of 
P.aeruginosa 
isolates 
Percentage (%) 
Burns 24 22.2 
Ventilator associated pneumonia 12 11.1 
Diabetes 8 7.4 
Otitis externa 4 3.7 
Keratitis 1 0.9 
Malignancy 1 0.9 
 
On analyzing various risk factors associated with Pseudomonas 
aeruginosa, 24 isolates were associated with burns, 12 were associated 
with ventilator associated pneumonia, 8 were associated with diabetes, 4 
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were associated with otitis externa, 1 was associated with keratitis and 1 
with malignancy. 
Table6. Antimicrobial susceptibility testing showing resistance pattern of 
P.aeruginosa by Disc diffusion method                                            n = 108                           
Antibiotic 
discs 
Zone size (mm) No .of 
resistant 
Isolates 
Percentage 
(%) Resistance 
(mm/less) 
Intermediate 
(mm) 
Sensitive 
(mm/more) 
Gentamicin 
(GEN) 10 µg 
12 13-14 15 42 39 
Amikacin 
(AK)30 µg 
14 15-16 17 80 74 
Norfloxacin 
(NX) 10 µg 
12 13-16 17 65 60 
Ciprofloxacin 
(CP) 5 µg 
15 16-20 21 77 71 
Netilmicin 
(NET) 30 µg 
12 13-14 15 44 41 
Ceftazidime 
(CAZ)30 µg 
14 15-17 18 24 22 
Ceftriaxone 
(CTR) 30 µg 
13 14-20 21 24 22 
Imipenem 
(IPM) 10 µg 
13 14-15 16 20 18.5 
Meropenem 
(MRP) 10 µg 
13 14-15 16 20 18.5 
Piperacillin+ 
Tazabactam 
(PT) 100/10 µg 
17 - 18 68 63 
Piperacillin 
(PI) 100 µg 
17 - 18 81 75 
Polymyxin B 
(PB) 300 µg 
11 - 12 0 0 
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Antimicrobial susceptibility testing of Pseudomonas aeruginosa 
isolates to various drugs like Piperacillin, Piperacillin-Tazabactam, 
Gentamycin, Amikacin, Norfloxacin, Ciprofloxacin, Netilmicin 
Ceftazidime, Ceftriaxone, Imipenem, Meropenem, and Polymyxin B was 
done. The percentage of P.aeruginosa isolates resistant to various drugs 
are shown in the above table. 
 
Table 7.  MIC determination of  P.aeruginosa by agar dilution method. 
                                                                                            n = 108  
                           
Imipenem (µg/ml)   Ceftazidime (µg/ml)  
<8 >8 <32 >32 
90(83.44%) 18 (16.66%) 88 (51.19%) 20 (18.5%) 
 
    Out of the 108 isolates, MIC determination by agar dilution method 
showed 18 isolates were having >8 MIC for Imipenem and 20 isolates 
were having >32 MIC for Ceftazidime.  
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Table 8.Number of isolates showing fourfold reduction in MIC with 
EDTA by agar   dilution method                                                         n=20   
                                                   
Imipenem with EDTA      Ceftazidime with EDTA     
18 (90%) 19 (95 %) 
 
      By agar dilution method the MIC of Imipenem and Ceftazidime along 
with EDTA was determined. The Table above shows the number of 
isolates which shows fourfold reduction in MIC with EDTA when 
combined with Imipenem and ceftazidime. 
18 isolates showed fourfold reduction with Imipenem when 
combined with EDTA and 19 isolates showed reduction of four fold in 
MIC with Ceftazidime when combined with EDTA.  
 
 
 
 
 
 
 
 
73 
 
Table 9.Metallo-β-lactamases detection by various phenotypic methods   
             n=20 
 
Out of the 20 isolates which were screening positive, Agar dilution 
(IMP + EDTA) detected 18 isolates, Agar dilution (CAZ+ EDTA) 
detected 19 isolates, Modified Hodge test detected 12 isolates, E test 
detected 19 isolates, DDST(I+EDTA) detected 17 isolates, DDST 
(CAZ+EDTA) detected 18 isolates, CDDT (I+EDTA) detected 17  
isolates and CDDT (CAZ+EDTA) detected 19 isolates  as MBL 
producers. 
 
Table10. MBL detection by Genotypic method (PCR)       n= 20 
 
Gene 
 
IMP alone 
 
IMP & VIM 
(Both) 
Total positives 
No. of isolates 
amplified 
17(85%) 1(5%) 18 (90%) 
 
 
Method 
Agar dilution(MIC) E test 
(MIC) 
Modified 
Hodge 
test 
Double Disc 
SynergyTest 
Combined Disc 
Diffusion Test 
I+EDTA CAZ+EDTA I+EDTA CAZ+EDTA I+EDTA CAZ+EDTA 
No. Of 
isolates 
& % 
18(90%) 19(95%) 19(95%) 12(60%) 17(85%) 18(90%) 17(85%) 19(95%) 
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Out of the 20 isolates subjected to PCR, 17 isolates were positive 
for IMP gene and 1 isolate was positive for both IMP and VIM gene. 
Table No.11 Age distribution of MBL producing Pseudomonas 
aeruginosa isolates         n = 18 
Age No. of isolates Percentage (%) 
<1 1 5.55 
1-10 1 5.55 
11-20 2 11.11 
21-30 2 11.11 
31-40 8 44.44 
41-50 1 5.55 
51-60 2 11.11 
>60 1 5.55 
 
 Out of the 18 isolates, 1 isolate was form <1 year age group, 1 
from 1-10 years, 2 from 11-20 years, 2 from 21-30 years,8 from 31-40 
years,1 from 41-50 years, 2 from 51-60 years and  1from  > 60 years age 
group.  
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Table .12 Sex distribution of MBL producing Pseudomonas aeruginosa         
isolates             n = 18 
Male Female 
13(72.22%) 5(27.78%) 
 
The sex distribution of MBL producing Pseudomonas aeruginosa 
in the clinical isolates was analysed and 13 isolates were from male 
patients and 7 isolates were from female patients. 
 
Table .13 Specimen wise distribution of MBL producing Pseudomonas 
aeruginosa                   n=18 
Specimen No. of isolates Percentage (%) 
Pus 3 16.67 
Wound swab 9 50.00 
Sputum 3 16.67 
Urine 2 11.11 
Body fluids 1 5.56 
 
The specimen wise distribution of MBL producing Pseudomonas 
was analysed and MBL positive isolates in pus sample were 3, 9 from 
wound swab, 3 from sputum, 2 from urine and 1 from body fluids.  
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Table14. Risk factors associated with MBL production                    n=18 
 
Risk factors No. of isolates Percentage (%) 
Burns 8 44.44 
On prolonged 
Ventilatory support 
4 22.22 
Diabetes 2 11.11 
Malignancy 1 5.56 
Surgery/Post op wound 
infection 
1 5.56 
Longer Hospital stay 1 5.56 
Prolonged use of 
Antibiotics 
1 5.56 
 
On analysis of the various risk factors associated with MBL 
production in pseudomonas, it was observed that 8 isolates were 
associated with burns, 4 with prolonged ventilatory support 2 with 
diabetes, 1 with malignancy, 1 with surgery/post op wound infection, 1 
with longer hospital stay and 1 with prolonged use of antibiotics.  
Various phenotypic methods were compared with PCR and the 
Sensitivity, Specificity, PPV and NPV are shown in Tables 15 to22. 
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   Table15. Comparison of Modified Hodge Test with PCR 
 
 
P value: 0.147.  
 
 
 
 
Table16. Comparison of Double Disc Synergy Test (IPM+EDTA)  
                 with PCR 
 
 
 
 
 
DDST 
(IPM+ 
EDTA) 
 
PCR 
Sensitivity 
With 95%CI 
Specificity 
With 95% CI 
PPV 
With 
95%CI 
NPV 
With 
95%CI 
positive negative Total  
 
 
89% (67-97) 
 
 
 
50%(9-91) 
 
 
 
94% 
(73-99) 
 
 
 
33% 
(6-79) 
Positive 16(94.1%) 1(5.9%) 17(100%) 
negative 2(66.7%) 1(33.3%) 3(100%) 
total 18(90%) 2(10%) 20(100%) 
 
P value: 0.284.  
 
 
 
 
 
 
 
 
 
MHT 
 
PCR 
Sensitivity(%) 
With 95%CI 
Specificity(%) 
With 95% CI 
PPV(%) 
With 
95%CI 
NPV(%) 
With 
95%CI 
positive negative Total  
 
 
67% (44-84) 
 
 
 
100%(34-100) 
 
 
 
100% 
(76-100) 
 
 
 
25% 
(7-59) 
Positive 12(100%) 0(0%) 12(100%) 
negative 6(75%) 2(25%) 8(100%) 
total 18(90%) 2(10%) 20(100%) 
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Table17. Comparison of Double Disc Synergy Test (CAZ+EDTA) 
                  with PCR 
 
P value: 0.195. 
 
 
 
 
 
 
Table18. Comparison of Combined Disc Diffusion Test (IPM+EDTA) 
               with PCR 
 
P value: 0.284. 
 
 
 
 
 
 
 
 
 
 
 
DDST 
(CAZ+ 
EDTA) 
 
PCR 
Sensitivity 
With 95%CI 
Specificity 
With 95% CI 
PPV 
With 
95%CI 
NPV 
With 
95%CI 
positive negative Total  
 
 
94% (74-99) 
 
 
 
50%(9-91) 
 
 
 
94% 
(74-99) 
 
 
 
50% 
(9-91) 
Positive 17(94.4%) 1(5.6%) 18(100%) 
negative 1(50%) 1(50%) 2(100%) 
total 18(90%) 2(10%) 20(100%) 
 
 
 
 
 
CDDT 
(IPM+ 
EDTA) 
 
PCR 
Sensitivity 
With 95%CI 
Specificity 
With 95% CI 
PPV 
With 
95%CI 
NPV 
With 
95%CI 
positive negative Total  
 
 
94% (74-99) 
 
 
 
50%(9-91) 
 
 
 
94% 
(74-99) 
 
 
 
50% 
(9-91) 
Positive 16(94.1%) 1(5.9%) 17(100%) 
negative 2(66.7%) 1(33.3%) 3(100%) 
total 18(90%) 2(10%) 20(100%) 
79 
 
Table19. Comparison of Combined Disc Diffusion Test (CAZ+EDTA) 
              with PCR 
 
 
 
 
 
CDDT 
(CAZ+ 
EDTA) 
 
PCR 
Sensitivity 
With 
95%CI 
Specificity 
With 95% CI 
PPV 
With 
95%CI 
NPV 
With 
95%CI 
positive negative Total  
 
 
100%  
(74-99) 
 
 
 
50%(9-91) 
 
 
 
95% 
(75-99) 
 
 
 
100% 
(21-100) 
Positive 18(94.7%) 1(5.3%) 19(100%) 
negative (0%) 1(100%) 3(100%) 
total 18(90%) 2(10%) 20(100%) 
 
P value : 0.100. 
 
 
 
 
 
  
Table20. Comparison of E Test (IPM+EDTA) with PCR 
 
 
 
 
 
 
E test 
 
PCR 
Sensitivity 
With 95%CI 
Specificity 
With 95% CI 
PPV 
With 
95%CI 
NPV 
With 
95%CI 
positive negative Total  
 
 
   100% 
 (82-100) 
 
 
 
50%(9-91) 
 
 
 
95% 
(75-99) 
 
 
 
100% 
(21-100) 
Positive 18(94.7%) 1(5.3%) 19(100%) 
negative 0(0%) 1(100%) 1(100%) 
total 18(90%) 2(10%) 20(100%) 
 
P value : 0.100.  
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Table21. Comparison of Agar Dilution method (IPM+EDTA) with PCR 
 
P value : 0.195.  
 
 
 
 
Table22. Comparison of Agar Dilution method (CAZ+EDTA)  with PCR 
 
 
 
 
 
Agar 
Dilution 
method 
(CAZ+
EDTA)  
 
 
PCR 
Sensitivity 
With 95%CI 
Specificity 
With 95% CI 
PPV 
With 
95%CI 
NPV 
With 
95%CI 
positive negative Total  
 
 
   100% 
 (82-100) 
 
 
 
50%(9-91) 
 
 
 
95% 
(75-99) 
 
 
 
100% 
(21-100) 
Positive 18(94.7%) 1(5.3%) 19(100%) 
negative 0(0%) 1(100%) 1(100%) 
total 18(90%) 2(10%) 20(100%) 
 
P value :0.100.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Agar 
Dilution 
method 
(IPM+ 
EDTA) 
 
PCR 
Sensitivity 
With 95%CI 
Specificity 
With 95% CI 
PPV 
With 
95%CI 
NPV 
With 
95%CI 
positive negative Total  
 
 
94% (74-99) 
 
 
 
 
50%(9-91) 
 
 
 
94% 
(74-99) 
 
 
 
50% 
(9-91) 
Positive 17(94.4%) 1(5.6%) 18(100%) 
negative 1(50%) 1(50%) 2(100%) 
total 18(90%) 2(10%) 20(100%) 
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Table23. Comparison of PCR with other Phenotypic methods       n=20 
 
 
Methods True 
positives 
False 
negatives 
False 
positives 
True 
negatives 
PCR 18 - - 2 
Agar 
dilution(IPM+EDTA) 
17 1 1 1 
Agar 
dilution(CAZ+EDTA) 
18 0 1 1 
E test 18 0 1 1 
MHT 12 6 0 2 
DDST(IPM+EDTA) 16 2 1 1 
DDST(CAZ+EDTA) 17 1 1 1 
CDDT(IPM+EDTA) 16 2 1 1 
CDDT(CAZ+EDTA) 18 0 1 1 
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Table24. Sensitivity and Specificity of various Phenotypic methods 
 
 
Methods Sensitivity Specificity PPV NPV P value 
Agar 
dilution(IPM+EDTA) 
94 50 94 50 0.195 
Agar 
dilution(CAZ+EDTA) 
100 50 95 100 0.100 
E test 100 50 95 100 0.100 
MHT 67 100 100 25 0.147 
DDST(IPM+EDTA) 89 50 94 33 0.284 
DDST(CAZ+EDTA) 94 50 94 50 0.195 
CDDT(IPM+EDTA) 89 50 94 33 0.284 
CDDT(CAZ+EDTA) 100 50 95 100 0.100 
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DISCUSSION 
 
 
               Pseudomonas aeruginosa is one of the leading causes of 
nosocomial infections giving rise to a wide range of life threatening 
conditions. The intrinsic resistance exhibited by Pseudomonas to a wide 
range of antibiotics imposes a serious therapeutic problem. Carbapenems 
are useful antimicrobial agents for the treatment of infections caused by 
Pseudomonas aeruginosa. However, with the increasing use of these 
compounds to treat the life threatening conditions, Carbapenem resistant 
P.aeruginosa has developed. The prevalence of metallo-beta-lactamase, 
one of the carbapenemases in Pseudomonas is of serious concern in the 
recent years worldwide. As there are currently no standard guidelines 
described so far, several studies have been undertaken worldwide to 
detect the MBL production. Hence, early identification of MBL 
production is of great clinical significance in combating the resistance. In 
view of this, the present study was undertaken to identify a simple and 
reproducible screening method to detect MBL in this institution. 
              A total of 580 samples were processed in the present study, the 
predominant isolate among all the isolates were the Gram-negative bacilli 
and out of 580 samples, 202(34.82%) were Gram-negative bacilli and 
108(18.62%) were P.aeruginosa. Out of the 108 P.aeruginosa , more 
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number of isolates 33(30.5%) were isolated from pus samples  followed 
by 24(22.2%) from wound swab. It was also inferred that more number of 
Pseudomonas isolates were isolated from 41- 50 years (19.44%) age 
group followed by 31-40 years (18.51%) age group. Analysis of sex wise 
distribution of Pseudomonas infection showed that most of Pseudomonas 
infections were associated with males (56%) than females (44%). A 
recent study done by Ramprasad Balikaran et al.,(2010) [111]  also reported 
the  highest incidence of Pseudomonas aeruginosa  were among males 
than females.The various risk factors associated with Pseudomonas 
infection were analysed and it was inferred that P.aeruginosa were 
predominantly isolated 24(22.2%) from burns patients followed by 
12(11.1%) from patients on ventilatory support . Seema Bose et al., 
2012[120] studied the incidence of MBL in P.aeruginosa  in burns patients 
for a period of nine months and explained the high rate(15.71%) of 
infection in burns patients with Pseudomonas could be due to the loss of 
protective barrier of skin and  the presence of devitalised tissues 
enhancing the growth of microorganisms and inhibiting the penetration of 
systemically administered antibiotics mediating drug resistance. 
           In India, the prevalence of Metallo-Beta-Lactamases in 
Pseudomonas ranging from 8 to 14% has been documented (Hirakata et 
al., 1998; Varaiya et al., 2008; Zavascki et al., 2006) [47,130,143]
. 
85 
 
          Various studies have reported the use of different methods for the 
detection of MBLs like Imipenem-EDTA combined disc test, Double disc 
synergy test using Imipenem-EDTA and Ceftazidime with EDTA, E test 
and Modified Hodge test (Behera et al.,2008;Arakawa et al.,2000;Lee et 
al.,2003;Yong et al.,2002;) [9,7,66,140]
. 
            In this study, MBL screening and confirmation was done by 
phenotypic and genotypic methods. The phenotypic methods used were 
the MIC determination by Agar dilution method using Imipenem and 
Ceftazidime in combination with EDTA to detect the four fold reduction 
in MIC, Combined disc diffusion test  using Imipenem and Ceftazidime 
with EDTA, Double disc synergy test using Imipenem and Ceftazidime 
with EDTA, E test to detect MIC and Modified Hodge test. These 
phenotypic methods were compared with the genotypic method for 
sensitivity and specificity. 
             With the Phenotypic and genotypic methods used to detect MBL 
in this study, it was found that 18.5%(18/108) isolates were resistant to 
Imipenem, 20.37%(20/108) were resistant to Ceftazidime and the 
prevalence of MBL in this institution was found to be 16.66% which is 
slightly closer to prevalence reported by Hemalatha et al., 2005[44] and 
Seema et al., 2012[120].  
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 Bashir et al., 2011[12] reported that out of the 132(46.6%) P.aeruginosa 
isolates, 38(13.42%) were resistant to Imipenem and out of which 
33(11.66%) were MBL producers. Hemalatha et al., 2005[44] reported 
16% of Pseudomonas aeruginosa isolates were resistant to Imipenem and 
14 % were positive for MBL production by Combined disc test. Behera 
et al., (2008)[9] reported 14.47% of  P.aeruginosa were resistant to 
Imipenem and 10.53% positive for MBL production by combined disc 
test. Agrawa et al., [1] reported 8.05% Imipenem resistance and 10.35% 
Ceftazidime resistance in MBL producers. Sarkar et al., 2006 [117] 
documented 36.36% resistance to Imipenem and 53.2% were MBL 
positive. Navaneeth et al., 2002[90] reported 12% MBL mediated 
Imipenem resistance in P.aeruginosa. Mihani et al., 2007[86] documented 
19.51% Imipenem resistant P.aeruginosa strains isolated from burns 
patients were MBL producers. Seema et al., 2012[120] reported 30% 
Imipenem resistance, out of which 20(14.28%) were non-MBL producers 
and 22(15.71%) were MBL producers. But in this study 44.44 % of 
burned patients infected with P.aeruginosa were MBL producers which 
were slightly higher than the other studies.  
      Bashir et al., 2011[12] reported the mean age of the patients from 
whom MBL producers were isolated was 50.66 years. The highest 
number of cases was above 60 years of age. In this study, most of the 
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MBL producing isolates  were from the age group 31- 40 years(44.44%) 
showing a lower preponderance in contrast to the age documented by 
Bashir et al.,2011 [12]. This could be due to the fact that most of the male 
patients inflicted with burns were in the 31 – 40 years age group and the 
suicidal risk is more common in that age group.  
      Out of 18 patients from whom MBL producers were isolated in this 
study, 13(72.22%) were males and 5(27.78%) were females and similar 
male preponderance was documented by Bashir et al., 2011 [12] also and 
in their study 51.5% were males and 48.5% were females which was not 
statistically significant (P>0.05). Debasrita Chakraborty et al., 2010[26]
 
also documented that male patients were predominantly affected with 
MBLs than females. 
      In this study, the predominant source of MBL positive strains was 
from wound swab 9(50%), followed by sputum 3(16.67%), pus 
3(16.67%), urine 2(11.11%) and body fluids 1(5.56%). Hirakata et al., 
1998[47] reported that the predominant source of MBL as urinary tract 
(40%).  Bashir et al., 2011[12], documented the predominant source of 
MBL positive strain from urinary tract 9(27.3%) followed by wound 
swab 2(24.2%) blood 6(18.2%), sputum 4(12.1%),CSF 3(9.1%),pus 
2(6.1%) and endotracheal tip 1(3%). 
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This shows that the predominant source of MBL positive strain 
was wound swab in our study which is in total contrast to study 
conducted by Bashir et al[12 ] and Hirakata et al[467] where the urinary tract 
was the predominant source. 
          On analysis of the various risk factors associated with MBL 
production in pseudomonas in this study, it was inferred that 44.44% 
isolates were from burns patients, 22.22% from patients with prolonged 
ventilatory support, 11.11% from diabetic patients, 5.56 % from 
malignancy, 5.56 % surgery/post op wound infection, 5.56 % from 
prolonged hospital stay and 5.56 % with prolonged use of antibiotics. 
Bashir et al.,2011[12 ]  reported that 24.2% of MBLs were isolated from 
patients with malignancy,15.2% from patients with diabetes,15.2% from 
patients with sepsis,12.1% from patients with cardiovascular 
disease,12.1% from patients with CNS infections,12.1% from patients 
with trauma,9.1% from patients with burns. This indicates that burns 
patients have significant risk association for MBL in the current study 
which was not significantly associated with study conducted by Bashir et 
al [12] who documented burns as the least risk factor for MBL production. 
But Seema Bose et al., 2012[120] reported the incidence of 15.71% of 
MBL from burns patients. So, it was inferred that burns wound has risk 
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association with MBL and the prevalence was found to vary in different 
health care settings. 
         In this study the antimicrobial susceptibility of various 
P.aeruginosa isolates revealed varied levels of resistance to 
antipseudomonal penicillins, third generation cephalosporins, 
aminoglycosides and fluoroquinolones. Polymyxin B was the most 
effective antibiotic in treating P.aeruginosa infections with no 
documented resistance which  was acknowledged in  study conducted by 
Sarkar et al.,2006 [117 ]
. 
           In the present study, the resistance to Imipenem and Meropenem 
were 18.5% for both the drugs and 22% resistance was recorded for 
Ceftazidime  by Kirby-Bauer disc diffusion method and 18.5% for 
Ceftazidime and 16.66% for Imipenem  by MIC agar dilution method 
which was in close concordance with Shahid et al.,2004 [122 ] who 
reported 20% Ceftazidime resistance. In the present study, 4 isolates 
which showed resistance for Ceftazidime by disc method were sensitive 
by Agar dilution method and 2 isolates which showed resistance for 
Imipenem by disc diffusion method were sensitive by Agar dilution 
method. MIC was also determined by combining EDTA with Imipenem 
and Ceftazidime individually to note the four fold reduction in MIC 
which indicated MBL production. It was inferred that 100% of the 
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isolates which showed resistance with disc method showed 4 fold 
reduction in MIC with EDTA for Imipenem but for Ceftazidime, 1 isolate 
out of the 20 which showed resistance did not show 4 fold reduction in 
MIC with EDTA indicated that some other resistance mechanism (could 
be ESBL) for Ceftazidime resistance other than MBL production.    
           Pitt et al.,2003[109 ] reported 39.6% Ceftazidime resistance in their 
study and  Debasrita Chakraborty et al.,2010[26] reported 100% resistance 
to third generation cephalosporins (Ceftazidime, Cefotaxime and 
Ceftriaxone) in MBL positive isolates of P.aeruginosa and 78.25% 
resistance for Imipenem  in a  study conducted in ICU patients. Agrawal 
et al., 2008[1] reported 40.22% resistance to Piperacillin. Sarkar et al., 
2006 [117] and Pitt et al., 2003[109] observed 12% and 31.9% resistance 
against Piperacillin respectively. In the present study, 75% resistance was 
observed against Piperacillin which is much higher from the other 
studies. This may be due to the indiscriminate use of this drug in our 
locality which has resulted in higher percentage of resistance.  
         Agrawa et al.,2008 [1] reported least resistance with Amikacin 
whereas Sarkar et al [117 ] found 40.90% resistance with Amikacin,45.45% 
with Gentamicin,59.09% with Tobramycin, and 50.5% with Netilmycin.         
        In this study, 74% resistance with Amikacin, 60% with Norfloxacin, 
71% with Ciprofloxacin, 22% with Ceftriaxone, 39% with Gentamicin, 
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41% with Netilmycin, and 0% with Polymyxin B has been detected. It is 
inferred that the Changing resistance patterns in clinical isolates of 
P.aeruginosa in various localities as indicated by various studies indicate 
the fact that the commonly used antipseudomonal agents like 
Aminoglycosides, Quinolones and few third generation Cephalosporins 
show a higher percentage of resistance than the newer third generation 
cephalosporins like Ceftazidime and Carbapenems (Imipenem and 
Meropenem).Hence, the frequent and inadvertent usage of the different 
groups of drugs have resulted in increasing resistance patterns in the 
isolates and there seems to be emergence of resistance in the newer group 
of drugs like few Cephalosporins and Carbapenems also. But  Polymyxin 
B, which was the older drug has not been used frequently due to the drug 
toxicity showed 0% resistance pattern and found to be the one of the 
fewer options available in pipeline to treat the emerging MBL positive 
isolates of P.aeruginosa. 
       Nirav V.Pandya et al (2011) [96] used various phenotypic methods on 
isolates which were screened for MBL by Kirby-Bauer disc diffusion 
method. They isolated 27 out of 450 isolates as screening positive and 
further proceeded with phenotypic methods and reported 96.3% were 
MBL positive by combined disc diffusion test using Imipenem and 
EDTA and 81.48% were MBL positive by double disc synergy test using 
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Imipenem and EDTA. 85.19%   positive by combined disc diffusion test 
using Ceftazidime and EDTA,  44.44% positive by double disc synergy 
test using Ceftazidime. They reported a prevalence of 9.92% MBL. They 
inferred that CDDT using Imipenem followed by CDDT using 
Ceftazidime as the most sensitive methods in the detection of MBLs .On 
comparing the various published studies with the present study, the 
following interpretation was made. 
STUDY CDDT-
Imipenem 
DDST- 
Imipenem 
CDDT- 
Ceftazidime 
DDST- 
Ceftazidime 
Picao et al[106 ] 80% 82.6% 83% 45.7% 
Galani et al[34 ] 94.7% 100% 100% 77.9% 
Franklin et al[32 ] 100% 79% - - 
Present study 89% 89% 100% 94% 
         In the present study, CDDT- CAZ and DDST-CAZ could detect 
additional isolates than CDDT-IMP AND DDST-IMP. This indicates that 
Ceftazidime is a better screening   drug for MBL detection than 
Imipenem. With the emergence of Carbapenem sensitive MBLs as 
described by Yan et al 2004 [138] and Clare Franklin et al 2006 [20] . MBL 
genes which are hidden mediate MBL production where the isolates 
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show resistance to Ceftazidime but are susceptible to Carbapenems. 
Similarly, Hemalatha et al., (2005) [44] found that Ceftazidime with EDTA 
could pick up additional isolates of MBL producers. But Bashir et al 
2011[12] picked up more MBL positive isolates by Imipenem with EDTA 
than with Ceftazidime EDTA discs. This could be explained by the fact 
that MBL producing organism might have some other Ceftazidime 
resistance mechanisms. So, with such isolates ,CDDT using Ceftazidime 
will not show MBL production as suggested by Behera et al[9]
.
In our 
study, Ceftazidime seems to be a better drug in the  detection of MBLs 
than Imipenem and yet another fact that Imipenem is an unstable drug  
that might miss MBLs, owing to their susceptibility when tested alone. 
       Bashir et al., 2011[12] reported 100% positive results with E Test. 
Varaiya et al., 2008 [130] and Pitout et al., 2005 [108] reported 96% 
sensitivity with E test. In the present study, E test showed 100% 
sensitivity similar to study conducted by Bashir et al.,2011[12 ]
. 
      Lee et al.,2003[66] used  Hodge test as a simple screening test for MBL 
producing isolates ,but occasional isolates showed false negative results. 
Rizvi et al., 2009[116] found DDST using EDTA better than Hodge test. 
Attal Ro et al., 2010[8] reported two Imipenem resistant strains  were 
found to be Carbapenem hydrolysis negative by the Hodge test and 
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Modified Hodge test and the likely reason for the Imipenem resistance 
may be a mechanism other than Carbapenem hydrolysis such as 
decreased membrane permeability. They also used 50 mM of zinc 
sulphate to improve sensitivity of Hodge test & added 10 µl of 50 mM 
zinc sulphate to Imipenem discs for Modified Hodge test, DDST and 
CDDT. Similarly in this study, only 12 out of the 20 isolates were 
positive by Modified Hodge test showing the least sensitivity to identify 
MBLs when compared to other methods. 
          Seema bose et al., 2012[120] showed that DDST and MBL E test 
were both equally sensitive and easy to perform. Behera et a.,2008l[9 ] 
used four different methods for MBL detection and found that CDDT 
using Imipenem and EDTA as superior to DDST using Imipenem and 
EDTA and Cetazidime with EDTA as DDST had the major disadvantages 
of subjective interpretation of results in some instances. This is in 
concordance with the other published studies which have found that 
CDDT to be one of the most sensitive techniques for detecting MBLs. 
They also suggested with the emergence of Carbapenem sensitive MBLs, 
the concern of which isolates to be selected for phenotypic MBL 
detection is controversial and hence they suggested that the combined 
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disc method to be applied on all isolates which show resistance to 
Ceftazidime and Ticarcillin with Clavulanic acid. 
         Agrawal et al.,2008[1]  and Arakawa et al.,2000 [7 ] inferred that 
MBL producer may be Imipenem sensitive but might have high minimum 
inhibitory concentration for Ceftazidime and concluded that Ceftazidime 
could be better choice for detection of MBL production. Arakawa et 
al.,2000 [7] recommended the testing of the Ceftazidime resistant isolates 
for MBL production, since some MBL producing Gram negative bacteria 
were inhibited by the low concentration of Imipenem and they were 
difficult to detect and also desctribed that IMP -1 producers usually 
exhibit high level resistance to Ceftazidime and have a significant 
inhibitory effect on thiol compounds. But Lee et al., 2003[66] reported that 
in their study, not a single MBL producing isolate was detected among 
the Imipenem sensitive isolates. In Japan, Sugino et al used only 
Carbapenem resistant isolates for the screening of MBLs.  
    Though various phenotypic methods have been described so far in 
various studies for the detection of MBLs, an accurate method to detect 
the MBLs with high sensitivity and specificity has not been proved so far. 
PCR analysis was described as a reliable and accurate method in various 
studies by Franklin et al.,2006 [32 ] and Arakawa et al..,2000[7 ] and Pitout 
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et al.,2005[108] performed a duplex PCR assay with high sensitivity and 
specificity that could simultaneously detect both VIM and IMP  genes 
and also described that  PCR confirmation for MBLs to be performed as 
an important method in regional laboratories, as EDTA can give false 
positive results in IMP resistant isolates due to altered OprD levels as 
described by Conejo et al., [23] . Pandya et al., 2011 [96] and Conejo et    
al., [23] also described PCR as the gold standard test for the detection of 
MBL production. 
     Hence, considering PCR as the gold standard, IMP and VIM gene 
assay was done and out of the 20 isolates subjected, 17 isolates were 
positive for IMP gene alone and one isolate was positive for both IMP 
and VIM gene. From the genotypic detection method, 18(16.66%) 
isolates were confirmed to be MBL producers. 2 isolates which were not 
detected in this study might be carrying some other genes other than IMP 
and VIM genes. Senda et al.,1996[121] also documented that IMP and VIM 
as the most predominantly prevalent genes in MBL positive isolates.In 
this study, the various phenotypic methods were compared with PCR and 
Sensitivity, Specificity, PPV and NPV were determined. 
        On comparison of various phenotypic tests with PCR, it was inferred 
that Agar dilution method (IPM+EDTA) had 94% sensitivity, 50% 
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specificity, 94%PPV, 50% NPV and P value 0.195. Agar dilution method 
(CAZ+EDTA) had 100% sensitivity, 50% specificity, 95%PPV, 100% 
NPV and P value 0.100. E test had 100% sensitivity, 50% specificity, 
95%PPV, 100% NPV and P value 0.100. Modified Hodge Test test had 
67% sensitivity, 100% specificity, 100%PPV, 25% NPV and P value 
0.147. DDST (IPM+EDTA) had 89% sensitivity, 50% specificity, 
94%PPV, 33% NPV and P value 0.284. DDST (CAZ+EDTA) had 94% 
sensitivity, 50% specificity, 94%PPV, 50% NPV and P value 0.195. 
CDDT (IPM+EDTA) had 89% sensitivity, 50% specificity, 94%PPV, 
33% NPV and P value 0.284. CDDT (CAZ+EDTA) had 100% 
sensitivity, 50% specificity, 95%PPV, 100% NPV and P value 0.100. 
Since P value in all the tests were not <0.05, it was inferred that there 
was no statistically significant difference between PCR and other 
phenotypic methods in the detection of MBLs. Out of the 20 isolates 
which were resistant to Imipenem and Ceftazidime, PCR detected 18 
isolates as positive. Agar dilution method using Ceftazidime+ EDTA, E 
test and CDDT (CAZ+EDTA) also detected the same 18 isolates as 
positive showing their high sensitivity in detecting all the MBL positive 
isolates. Modified Hodge Test detected only 12 isolates as positive, 
indicating its least sensitivity when compared to PCR but there was no 
false positives and detected all the true negatives indicating high 
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specificity. All the phenotypic methods detected one isolate as falsely 
positive except MHT. Conejo et al., [23] explained that false positives have 
been reported with EDTA-based methods due to the effect of EDTA on a 
zinc-dependent OprD pump which is responsible for Carbapenem entry in 
the isolates. Hence in this study, three phenotypic methods i.e., 
CDDT(CAZ+EDTA), E test, Agar dilution method using Ceftazidime + 
EDTA have equal sensitivity 100%, followed by DDST(CAZ+EDTA) & 
Agar dilution method (IPM+EDTA) 94% and DDST(IPM+EDTA) & 
CDDT(IPM+EDTA) 89% sensitivity. On analyzing the pros and cons of 
various methods, it is inferred that E test, though a highly sensitive 
method could not be done in all laboratories due to cost constraints and 
Agar dilution method being  a cumbersome procedure and time 
consuming  could not be routinely employed for MBL detection in all 
laboratories.  
        CDDT (CAZ+EDTA) is a simple, cost effective and easiest 
method with sensitivity very close to PCR in detecting all the MBL 
positive isolates. It was also inferred that an MBL producer may be 
Imipenem sensitive but might have high MIC for Ceftazidime and hence 
Ceftazidime is a better drug for MBL detection as described by Arakawa 
et al., 2000[7]
.
As PCR cannot be done in every laboratory due to its high 
99 
 
cost and the need for a sophisticated set up and trained personnel, the 
introduction of a simple and cost effective method to detect all the MBLs 
is the need of the hour in any diagnostic Microbiology laboratory for 
effective infection control and to prevent therapeutic failure and also to 
prevent dissemination of resistant strains in the health care settings as 
well as in the  community.   
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SUMMARY 
 The study showed a preponderance of Gram negative infections 
(53.44%) among various samples and out of which 18.63% were 
Pseudomonas aeruginosa. 
 Among the Pseudomonas aeruginosa isolates 16.66% were MBL 
producers. 
 50% of MBL producers were isolated from wound swab collected 
from burns wounds. 
 44.44% of MBL producers were from 31-40 years and 5.55%of 
MBL producers were equally distributed in the extremes of age 
group. 
 72.22% of males and 27.78% of females were MBL producers 
showing male predominance. 
 MBL has been most commonly associated with risk factors like 
burns (44.44%) and ventilator associated pneumonia (22.22%). 
 Various phenotypic methods were used for the detection of MBLs 
and compared with PCR (IMP & VIM gene assay) as gold 
standard. 
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 Out of the 20 screening positive isolates, IMP gene alone was 
detected in 85% of isolates and both IMP & VIM genes were 
detected in 5% of isolates. 
 CDDT (CAZ+EDTA), E test, Agar dilution method using 
Ceftazidime + EDTA have equal sensitivity of 100% in detecting 
MBLs and are as sensitive as PCR. 
 CDDT (CAZ+EDTA) is a simple, cost effective and easiest 
method with sensitivity very close to PCR in detecting all the MBL 
producing P.aeruginosa isolates. 
 Carbapenem sensitive but Ceftazidime resistant MBL positive 
isolates were detected and Ceftazidime was found to be the better 
substrate drug in detecting all the MBLs in the present study. 
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CONCLUSION 
 The emergence of Gram negative bacterial species with acquired 
resistance to various broad spectrum Beta lactam antibiotics has 
become a clinical problem worldwide and particularly Pseudomonas is 
notorious for causing a wide range of hospital acquired infections. 
 In this study, Carbapenem sensitive MetalloBetaLactamases in 
Pseudomonas aeruginosa have been found emerging predominantly 
from burns ward in Govt. Rajaji hospital, Madurai with a prevalence 
of 16.66% with a predilection to affect males of the middle age group 
(31- 40 years). 
 Early detection of these strains is crucial to establish an appropriate 
antimicrobial therapy and to prevent interhospital and intrahospital 
dissemination and thereby reduce the mortality and morbidity 
associated with these infections.  
 On comparison of various phenotypic methods, Combined Disc 
Diffusion Test  using Ceftazidime and EDTA was found to be the 
simple, cost effective and highly sensitive method close to PCR  to 
detect all the carbapenem susceptible MBLs with hidden MBL genes 
which are a serious threat to infection control efforts. 
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 Formulating antibiotic policy, judicial use of higher antibiotics, 
isolation of MBL infected patients, strict safety precautions such as use 
of gloves, masks gowns and proper hand washing techniques are the 
measures that can be taken to combat the serious therapeutic challenge 
faced with MBL producing isolates. 
 With only a fewer drugs available in the pipeline like Polymyxin B, 
Colistin (Polymyxin E), Rifampicin and Tigecycline, the judicious 
selection of antibiotics to treat MBL producing isolates should be 
implemented. 
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ANNEXURE – 1    
PREPARATION OF GRAM STAIN 
GRAM STAIN REAGENTS 
1. Methyl violet - Primary stain 
    Methyl violet 10 g 
    95% ethyl alcohol 100 ml 
    Distilled water 1 L 
2. Gram’s Iodine – Mordant 
     Iodine 10 g 
     Potassium iodide 20g 
     Distilled water 1 L 
3. Acetone - Decolouriser 
4. Dilute Carbol Fuchsin  - Counter stain 
    Basic fuchsin 0.3g 
    95% Ethyl alcohol 10 ml 
    Phenol crystals, melted 5 ml 
    Distilled water 95 ml 
Basic fuchsin was dissolved in alcohol.5 % phenol solution was added and was 
allowed to stand overnight. Then the solution filtered through coarse filter paper.  
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ANNEXURE - 2 
PREPARATION OF MEDIA 
PREPARATION OF NUTRIENT AGAR 
Contents: 
 Peptone – 5g 
 Beef extract – 1.5 g 
 Yeast extract – 1.5g 
 Sodium chloride – 5g 
 Agar – 15g 
28 g of the contents were suspended in 1000 ml of distilled water. It was heated to 
boiling to dispense the medium completely. Medium was sterilised by autoclaving at 
121 ˚ c at 15 lbs pressure for 15 minutes. 
PREPARATION OF MAC KONKEY AGAR 
Contents: 
Sodium taurocholate 5.0 g 
Peptone 20.0 gm 
Sodium chloride 5.0 g 
Lactose 10.0 g 
Agar 15.0 g 
Distilled water 1000 ml 
Neutral red (2% solution in 50% ethanol) 3.5 ml 
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  5 g sodium taurocholate or bile salts, 20 g of peptone, 5 g sodium chloride 
and 15 g agar were mixed with 1000 ml water. 
  Steamed until the solids were dissolved. 
  Cooled to about 50˚ C, and at this temperature the reaction was adjusted to pH 
7.5 to 7.8. Autoclaved at 121˚C for 15 minutes and filtered while hot through 
 a good grade of filter paper, or a plug of cotton wrapped in gauze  placed in 
the funnel. 
 The  reaction of the filtrate was adjusted to pH 7.3 at 50˚C or pH 7.5 at room 
temperature. 10 gm lactose and 3.5 ml of 2% solution of neutral red in 50% 
ethanol were added. Mixed thoroughly and distributed in flasks and sterilized 
in the autoclave at 121˚C for 15 minutes. 
  For use, melted in the steamer, poured into sterile petri dishes and allowed 
 to set. 
 
PREPARARION OF BLOOD AGAR 
 
Nutrient agar 100 ml 
Sheep blood (defibrinated) 10 ml 
 The sterile nutrient agar was melted by steaming and cooled to 45˚C. 
 5% -10% sheep blood was added aseptically with constant  shaking. 
 The blood was mixed with molten nutrient agar thoroughly but gently, to 
avoid froth formation.To remove the bubbles,media was flamed. 
 Immediately poured into petri dishes and allowed to set. 
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PREPARATION OF MUELLER – HINTON AGAR   
Contents: 
Beef extract 2.0 gm 
Acidicase Peptone 17.5 gm 
Starch 1.5 gm 
Agar 17.0 gm 
Distilled water 1000 ml 
Final pH 7.4 + 0.2 
Dissolved the ingredients in one liter of distilled water. Mixed thoroughly. Heated 
with frequent agitation and boiled for one minute. Dispensed and sterilized by 
autoclaving at 121˚C for 15 minutes. Should not be overheated. When remelting the 
sterile medium, heated as briefly as  possible. 
 
PREPARATION OF TSI MEDIUM: 
Contents: 
Beef extract 3g                                      
Yeast extract 3g 
Peptone 20g 
Glucose 1g 
Lactose 10g 
Sucrose 10g 
Ferric citrate 0.3g 
Sodium chloride 5g 
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Sodium thiosulphate 0.3g 
Agar 12g 
Phenol red 0.2% 
Distilled water 1 L 
The solids were heated to dissolve and the indicator solution was added, mixed and 
tubed. Sterilized at 121˚c for 15 minutes and cooled to form slopes with deep (3 cm) 
butts. 
PREPARATION OF CITRATE MEDIUM: 
Contents: 
Sodium chloride 5g 
Magnesium sulphate 0.2g 
Ammonium dihydrogen phosphate 1g 
Sodium citrate 5g 
Agar 20 g 
Bromothmol blue 0.2% 40 ml 
Distilled water 1 litre 
The above contents were dispensed and autoclaved at 121˚c for 15 minutes and 
allowed to set as slopes. 
PREPARATION OF  OXIDATION-FERMENTATION MEDIUM: 
Contents: 
Peptone 2g 
Sodium chloride 5g 
Dipotassium hydrogen phosphate 0.3g 
Bromothymol blue (1 % aqeous solution) 0.03g 
Agar 3g 
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Distilled water 1000 ml 
The pH was adjusted to 7.1 before adding the bromothymol blue and the medium was 
autoclaved in a flask at 121˚c for 15 minutes. The carbohydrate(Glucose) to be added 
was sterilized separately and added to give a final concentration of 1%.The medium 
was then tubed to a depth of about 4 cm. 
PREPARATION OF NITRATE MEDIUM: 
Contents: 
Potassium nitrate 0.2g 
Peptone 5g 
Distilled water 1000ml 
The above contents were mixed and tubed in 5 ml amounts and autoclaved at 121˚c 
for 15 minutes. 
Test reagent: 
Solution A: 8 g of sulphanilic acid was dissolved in 1 L of acetic acid 5 mol/litre 
Solution B:5 g of alpha-naphthlamine in 1 L of acetic acid 5 mol/litre. Immediately 
before use,equal volumes of solutions A and B were mixed to get the test reagent. 
PREPARATION OF ARGININE DIHYDROLASE TEST MEDIUM: 
Contents: 
Peptone 5g 
Meat extract 5g 
Glucose 0.5g 
Pyridoxal 5mg 
Bromocresol purple 5 mg (1 in 500 solution)    5ml 
Cresol red (1 in 500 solution)   2.5 ml      
Distilled water 1000 ml                    
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The solids were dissolved in water and the pH adjusted to 6.0 before the addition of 
indicators .This is the basal medium and to it was added the amino acid 1% L-arginine 
hydrochloride .1 ml quantities were distributed in small tubes and autoclaved at 121˚c 
for 15 minutes. Sterile liquid paraffin was added to provide a layer about 5 mm thick 
above the medium. 
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ANNEXURE -3 
                                  DATA COLLECTION PROFORMA 
1. Case No. 
2. Name and address of the patient: 
3. Age & sex: 
4. OP & IP No: 
5. Ward and Unit: 
6. Date of admission: 
7. Occupation and income: 
8. Clinical diagnosis: 
9. Relevant co-existing clinical conditions/illnesses: 
10. History of presenting illness: 
11. Past history: 
12. Personal history: 
13. Treatment History: 
     (Antibiotics taken if any) 
14. Sample collected: 
15. Date of sample collection: 
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FIG. 1 NUTRIENT AGAR PLATE SHOWING GREEN PIGMENTED COLONIES
FIG.2   MACKONKEY AGAR PLATE SHOWING NON
 
 
 
 
-LACTOSE FERMENTING COLONIES
 
 
 
 
FIG.3 BLOOD AGAR PLATE SHOWING METALLIC SHEEN AND BETA HEMOLYTIC COLONIES
    
 
 
 
 
 FIG.4 GRAM NEGATIVE BACILLI IN 
                DISCRETE PATTERN 
 
    
 
 
 
                             
                                          FIG.5   OXIDASE TEST           
                                                     
 
 
 
 
                                      
              
              FIG.6 CATALASE TEST
 
     
 
 
 
 
              FIG.8   O/F TEST                  
 
 
 
                          FIG.7 BIOCHEMICAL REACTIONS
                    
                      FIG.9 NITRATE REDUCTION TEST
                                  
 
 
  
 
 FIG.10 ARGININE DIHYDROLASE TEST
 
 
                                     
                                          
                                    FIG.12   
 
                                                                                                  
 
 
              FIG.11 GELATIN LIQUEFACTION TEST
                                  
ANTIBIOGRAM OF P.AERUGINOSA 
                     
MULTIDRUG RESISTANCE
CP 
NET 
CAZ
PI
GEN 
AK 
NX 
 
 
 
 
 
 
FIG.13 MEROPENEM   SUSCEPTIBLE
             P.AERUGINOSA                                                        
 
 
 
 
                            FIG.15 MIC DETERMINATION
 
       DRUG DILUTION                       
                                                                 
 
 
 - ATCC                               FIG.14   MEROPENEM   
                          RESISTANCE           
                     
-AGAR DILUTION METHOD
                    
                        MHA PLATES WITH IMIPENEM AND
                                    CEFTAZIDIME WITH SPOT INOCULATION
 
 
 
 
 
 
 
  FIG.16  DRUG CONTROL                               
 
 
 
 
FIG.18 CEFTAZIDIME RESISTANCE
             MIC-1024 µG                                                                 
         
 
 
                        FIG.17   IMIPENEM RESISTANCE
   MIC 16µG 
                              
-                      FIG.19   CEFTAZIDIME RESISTANCE
MIC - 512 µG 
                          
-          
 
-  
 
FIG20. MODIFIED HODGE TEST 
 
 
 
 
FIG.21 COMBINED DISC DIFFUSION TEST
              NON-MBL PRODUCER     
  
                                   
 
IPM, IPM+ EDTA - NO DIFFERENCE                   
– MBL PRODUCER 
                                
 – IMIPENEM AND CEFTAZIDIME 
 
                                           MBL PRODUCER
                
              IPM, IPM+EDTA > 5 MM  
 
 
WITH EDTA 
 
   
 DIFFERENCE 
FIG.22 COMBINED DISC DIFFUSION TEST
                                               CAZ, CAZ+EDTA
 
                   FIG.23 DOUBLE DISC SYNERGY TEST
                               
         
- CEFTAZIDIME WITH EDTA
MBL PRODUCER 
 
 > 5 MM DIFFERENCE 
- IMIPENEM WITH EDTA
MBL PRODUCER 
 
 
 
             FIG.24 DOUBLE DISC SYNERGY TEST
 
             NON-MBL PRODUCER                          
 
 
 
 
 
                                                                            
          NON-MBL PRODUCER                              
 
                                            
                                                                                                 
                                                         
- CEFTAZIDIME WITH EDTA
                   MBL PRODUCER
                                      
FIG.25 E TEST 
                    MBL-PRODUCER
IPM -   MIC- 16 µG, WITH EDTA <1 µG
 
 
 
 
 
 
FIG.25 
                                  
                                  
                                       IMP MIC
 
 
                        FIG. 26   MOLECULAR CHARACTERISATION
 
             THERMOCYCLER                                 
 
 
  E TEST   -    MBL PRODUCER 
 
-256 µG, WITH EDTA <1 µG 
- PCR 
                  SAMPLES LOADED
                                  
 
 
PALM CYCLER                               
     
 
        
FIG.27   PCR GEL
                                PC                T1                
 
  GEL ELECTROPHORESIS 
                          
 
 
 
 DOCUMENTATION PICTURE-IMP GENE
 
   T2          LADDER           T3 T4               T5 
 
 
 
 
FIG.27 PCR GEL DOCUMENTATION PICTURE
 
             PC             NC                 TEST             
FIG.28   PCR GEL DOCUMENTATION PICTURE
 
                
                                                              
-IMP GENE 
 
    DNA    LADDER 
 
-VIM GENE
    DNA  LADDER                                      TEST                    
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63 2155 51/M UTI Urine R R S S S S S S R R R S 1 0.5
64 13 35/F Ascites Asc fluid R S S S S S S S R R R S 4 0.5
65 918 60/F Burns WS R S S S S S S S R R R S 2 0.5
66 6 30/M Abs. L thigh Pus R R S S S S S S R R R S 2 2
67 812 45/M om Pus S S S S S S S S R S R S 2 4
68 805 52/M DM foot Pus S S S S S S S S R R R S 4 1
69 814 65/M Abscess Pus S S S S S S S S R S R S 2 0.5
70 678 65/M OE Pus S S S S S S S S R R R S 4 1
71 221 47/M SSI Pus R R S S S S S S R R R R 1 4
72 1132 28/M csom Pus R R S S S S S S R R R R 2 1
73 1128 40/M DM foot Pus R R R R R R S S S R R R 16 0.5 128 8 P P P P P P I
74 608 50/M Burns WS R R S S S S S R R R R R 2 4
75 1154 25/F Pyothorax Pus R R R R R R S R R R R R 0.5 0.5
76 1143 30/M crush injury Pus R R R R R R S R R R R R 1 4
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97 1206 9/365/Fch Pneumonia BAL R R R R S S S R R R R R 16 1 128 4 N P P P P P I
98 1209 24/F CRF Urine R R R R S S S IS R s R R 16 0.5 32 1 N P P P P P I
99 1341 13/M CCF Sputum R R S S S S R R R R R 1 8
100 907 32/M Burns WS R R R R R R S R R R R R 32 1 256 8 P P P P P P I
101 1339 60/F Pneumonia Sputum S S S S S S S R R R R R 1 8
102 1346 55/M empyema Sputum R R S S R R S R R R R R 1 2
103 1125 50/M UL cons Sputum R R S S S S S R R R R R 1 4
104 910 31/M Burns WS R R S S S S S R R R R R 1 4
105 913 27/F Burns WS R S S S R R S R R R R R 1 8
106 4848 3/Mch CP,MR,UTI Urine R R R R R R S R R R R R 16 0.5 1024 8 N P P P P P I +V
107 914 37/M Burns WS R R R R R R S R R R R R 32 2 256 16 P P P P P P I
108 927 65/M Pneumonia Sputum R R R R R R S R R R R R 32 2 256 8 P P P P P P I
Pne-Pneumonia WI-wound infection WS-wound swab CA rect - Carcinoma rectum SSI - Surgicial Site Infection
O.E - Otitis Externa pyelo - pyelo nephritis DM - Diabetes Mellitus I-IMP gene V-VIM gene 
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INTRODUCTION Pseudomonas aeruginosa has become one of the most dreadful causes of
nosocomial bacterial infections especially in the lung, blood and urinary tract. As a result of its
considerable potential to become resistant to many antibiotics more multidrug resistant strains are
encountered as clinical isolates, leaving physicians with a decreasing armamentarium of effective
drugs for treatment. Before the advent of modern medical microbiology, there was evidence that
P.aeruginosa was a cause of serious wound and surgical infections, as elaborated by Doggett .In
1850, it was noted by Sedillot that there were sometimes blue green discharges on surgical dressings
that were associated with...
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